1
|
Nishida T, Ayaori M, Arakawa J, Suenaga Y, Shiotani K, Uto-Kondo H, Komatsu T, Nakaya K, Endo Y, Sasaki M, Ikewaki K. Liver-specific Lxr inhibition represses reverse cholesterol transport in cholesterol-fed mice. Atherosclerosis 2024; 397:117578. [PMID: 38797615 DOI: 10.1016/j.atherosclerosis.2024.117578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 04/26/2024] [Accepted: 05/07/2024] [Indexed: 05/29/2024]
Abstract
BACKGROUND AND AIMS High density lipoprotein (HDL) exerts an anti-atherosclerotic effect via reverse cholesterol transport (RCT). Several phases of RCT are transcriptionally controlled by Liver X receptors (Lxrs). Although macrophage Lxrs reportedly promote RCT, it is still uncertain whether hepatic Lxrs affect RCT in vivo. METHODS To inhibit Lxr-dependent pathways in mouse livers, we performed hepatic overexpression of sulfotransferase family cytosolic 2B member 1 (Sult2b1) using adenoviral vector (Ad-Sult2b1). Ad-Sult2b1 or the control virus was intravenously injected into wild type mice and Lxrα/β double knockout mice, under a normal or high-cholesterol diet. A macrophage RCT assay and an HDL kinetic study were performed. RESULTS Hepatic Sult2b1 overexpression resulted in reduced expression of Lxr-target genes - ATP-binding cassette transporter G5/G8, cholesterol 7α hydroxylase and Lxrα itself - respectively reducing or increasing cholesterol levels in HDL and apolipoprotein B-containing lipoproteins (apoB-L). A macrophage RCT assay revealed that Sult2b1 overexpression inhibited fecal excretion of macrophage-derived 3H-cholesterol only under a high-cholesterol diet. In an HDL kinetic study, Ad-Sult2b1 promoted catabolism/hepatic uptake of HDL-derived cholesterol, thereby reducing fecal excretion. Finally, in Lxrα/β double knockout mice, hepatic Sult2b1 overexpression increased apoB-L levels, but there were no differences in HDL levels or RCT compared to the control, indicating that Sult2b1-mediated effects on HDL/RCT and apoB-L were distinct: the former was Lxr-dependent, but not the latter. CONCLUSIONS Hepatic Lxr inhibition negatively regulates circulating HDL levels and RCT by reducing Lxr-target gene expression.
Collapse
MESH Headings
- Animals
- Liver X Receptors/metabolism
- Liver X Receptors/genetics
- Liver/metabolism
- Mice, Knockout
- Biological Transport
- Mice
- Cholesterol/metabolism
- Macrophages/metabolism
- Mice, Inbred C57BL
- Sulfotransferases/metabolism
- Sulfotransferases/genetics
- ATP Binding Cassette Transporter, Subfamily G, Member 5/metabolism
- ATP Binding Cassette Transporter, Subfamily G, Member 5/genetics
- Cholesterol, Dietary
- ATP Binding Cassette Transporter, Subfamily G, Member 8/metabolism
- ATP Binding Cassette Transporter, Subfamily G, Member 8/genetics
- Male
- Cholesterol, HDL/blood
- Cholesterol, HDL/metabolism
- Lipoproteins, HDL/metabolism
- Lipoproteins
Collapse
Affiliation(s)
- Takafumi Nishida
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
| | - Makoto Ayaori
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan; Tokorozawa Heart Center, Tokorozawa, Japan
| | - Junko Arakawa
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Yumiko Suenaga
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Kazusa Shiotani
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Harumi Uto-Kondo
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Tomohiro Komatsu
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Kazuhiro Nakaya
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Yasuhiro Endo
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Makoto Sasaki
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| | - Katsunori Ikewaki
- Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
| |
Collapse
|
2
|
Li Z, Kang S, Kang H. Development and validation of nomograms for predicting cardiovascular disease risk in patients with prediabetes and diabetes. Sci Rep 2024; 14:20909. [PMID: 39245747 PMCID: PMC11381537 DOI: 10.1038/s41598-024-71904-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2024] [Accepted: 09/02/2024] [Indexed: 09/10/2024] Open
Abstract
This study aimed to develop and validate distinct nomogram models for assessing CVD risk in individuals with prediabetes and diabetes. In a cross-sectional study design, we examined data from 2294 prediabetes and 1037 diabetics who participated in the National Health and Nutrition Examination Survey, which was conducted in the United States of America between 2007 and 2018. The dataset was randomly divided into training and validation cohorts at a ratio of 0.75-0.25. The Boruta feature selection method was used in the training cohort to identify optimal predictors for CVD diagnosis. A web-based dynamic nomogram was developed using the selected features, which were validated in the validation cohort. The Hosmer-Lemeshow test was performed to assess the nomogram's stability and performance. Receiver operating characteristics and calibration curves were used to assess the effectiveness of the nomogram. The clinical applicability of the nomogram was evaluated using decision curve analysis and clinical impact curves. In the prediabetes cohort, the CVD risk prediction nomogram included nine risk factors: age, smoking status, platelet/lymphocyte ratio, platelet count, white blood cell count, red cell distribution width, lactate dehydrogenase level, sleep disorder, and hypertension. In the diabetes cohort, the CVD risk prediction nomogram included eleven risk factors: age, material status, smoking status, systemic inflammatory response index, neutrophil-to-lymphocyte ratio, red cell distribution width, lactate dehydrogenase, high-density lipoprotein cholesterol, sleep disorder, hypertension, and physical activity. The nomogram models developed in this study have good predictive and discriminant utility for predicting CVD risk in patients with prediabetes and diabetes.
Collapse
Affiliation(s)
- Zhao Li
- College of Sport Science, Sungkyunkwan University, 2066 Seoburo, 16419, Jangan-gu, Suwon, Republic of Korea
| | - Seamon Kang
- College of Sport Science, Sungkyunkwan University, 2066 Seoburo, 16419, Jangan-gu, Suwon, Republic of Korea
| | - Hyunsik Kang
- College of Sport Science, Sungkyunkwan University, 2066 Seoburo, 16419, Jangan-gu, Suwon, Republic of Korea.
| |
Collapse
|
3
|
Li H, Wang M, Qu K, Xu R, Zhu H. MP Allosterically Activates AMPK to Enhance ABCA1 Stability by Retarding the Calpain-Mediated Degradation Pathway. Int J Mol Sci 2023; 24:17280. [PMID: 38139111 PMCID: PMC10743971 DOI: 10.3390/ijms242417280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 12/01/2023] [Accepted: 12/05/2023] [Indexed: 12/24/2023] Open
Abstract
It is widely recognized that macrophage cholesterol efflux mediated by the ATP-binding cassette transporter A1 (ABCA1) constitutes the initial and rate-limiting step of reverse cholesterol transport (RCT), displaying a negative correlation with the development of atherosclerosis. Although the transcriptional regulation of ABCA1 has been extensively studied in previous research, the impact of post-translational regulation on its expression remains to be elucidated. In this study, we report an AMP-activated protein kinase (AMPK) agonist called ((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-((3-hydroxyphenyl) amino)-9H-purin-9-yl) tetrahydrofuran-2-yl) methyl dihydrogen phosphate (MP), which enhances ABCA1 expression through post-translational regulation rather than transcriptional regulation. By integrating the findings of multiple experiments, it is confirmed that MP directly binds to AMPK with a moderate binding affinity, subsequently triggering its allosteric activation. Further investigations conducted on macrophages unveil a novel mechanism through which MP modulates ABCA1 expression. Specifically, MP downregulates the Cav1.2 channel to obstruct the influx of extracellular Ca2+, thereby diminishing intracellular Ca2+ levels, suppressing calcium-activated calpain activity, and reducing the interaction strength between calpain and ABCA1. This cascade of events culminates in the deceleration of calpain-mediated degradation of ABCA1. In conclusion, MP emerges as a potentially promising candidate compound for developing agents aimed at enhancing ABCA1 stability and boosting cellular cholesterol efflux and RCT.
Collapse
Affiliation(s)
| | | | | | | | - Haibo Zhu
- State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Xian Nong Tan Street 1, Xicheng District, Beijing 100050, China; (H.L.); (M.W.); (K.Q.); (R.X.)
| |
Collapse
|
4
|
Luna-Castillo KP, López-Quintero A, Carrera-Quintanar L, Llamas-Covarrubias IM, Muñoz-Valle JF, Márquez-Sandoval F. The Influence of Lifestyle on High-Density Lipoprotein Concentration among Mexican Emerging Adults. Nutrients 2023; 15:4568. [PMID: 37960221 PMCID: PMC10649881 DOI: 10.3390/nu15214568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 10/21/2023] [Accepted: 10/25/2023] [Indexed: 11/15/2023] Open
Abstract
Previous studies have highlighted the role of lifestyle on HDL-C concentrations in adults. To our knowledge, the health and nutritional status of emerging adults have been understudied. The present study aimed to explore the most important lifestyle factors, including micronutrient intake adequacy and the percentage of energy from food processing, according to HDL-C concentrations in emerging adults. In this context, a cross-sectional analysis was conducted on 261 Mexican emerging adults who were apparently healthy. Lifestyle factors were collected through a structured survey and the prevalence of micronutrient intake inadequacy was estimated using the estimated average requirement cut-point method. The percentage of energy from ultra-processed foods was assessed using the NOVA system. HDL-C was determined using the enzymatic colorimetric method. Statistical analyses were conducted in SPSS. The results revealed that lifestyle factors do not differ according to HDL-C status. The participants showed a poor nutritional diet that was energy-dense and micronutrient-inadequate. Nearly half of their energy came from processed and ultra-processed foods. Most participants did not meet the recommendations for key nutrients (ϖ3 fatty acids and phytosterols) that promote a healthy lipid status. In conclusion, regardless of their HDL-C levels, emerging adults exhibited lifestyle-related risk factors. The persistence of these findings over time could contribute to the development of metabolic disorders in the future. It is crucial to increase understanding and to develop effective nutritional interventions during this critical phase of life.
Collapse
Affiliation(s)
- Karla Paulina Luna-Castillo
- Doctorado en Ciencias de la Nutrición Traslacional (DCNT), Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico; (K.P.L.-C.); (L.C.-Q.); (I.M.L.-C.); (J.F.M.-V.)
- Instituto de Nutrigenética y Nutrigenómica Traslacional (INNUGET), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico
| | - Andres López-Quintero
- Doctorado en Ciencias de la Nutrición Traslacional (DCNT), Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico; (K.P.L.-C.); (L.C.-Q.); (I.M.L.-C.); (J.F.M.-V.)
- Instituto de Nutrigenética y Nutrigenómica Traslacional (INNUGET), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico
| | - Lucrecia Carrera-Quintanar
- Doctorado en Ciencias de la Nutrición Traslacional (DCNT), Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico; (K.P.L.-C.); (L.C.-Q.); (I.M.L.-C.); (J.F.M.-V.)
- Instituto de Investigación en Cáncer en la Infancia y Adolescencia (INICIA), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico
| | - Iris Monserrat Llamas-Covarrubias
- Doctorado en Ciencias de la Nutrición Traslacional (DCNT), Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico; (K.P.L.-C.); (L.C.-Q.); (I.M.L.-C.); (J.F.M.-V.)
- Instituto de Nutrigenética y Nutrigenómica Traslacional (INNUGET), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico
| | - José Francisco Muñoz-Valle
- Doctorado en Ciencias de la Nutrición Traslacional (DCNT), Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico; (K.P.L.-C.); (L.C.-Q.); (I.M.L.-C.); (J.F.M.-V.)
- Instituto de Investigación en Ciencias Biomédicas (IICB), Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico
| | - Fabiola Márquez-Sandoval
- Doctorado en Ciencias de la Nutrición Traslacional (DCNT), Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), Guadalajara 44340, Jalisco, Mexico; (K.P.L.-C.); (L.C.-Q.); (I.M.L.-C.); (J.F.M.-V.)
| |
Collapse
|
5
|
Kobayashi M, Kanbe F, Ishii R, Tsubouchi H, Hirai K, Miyasaka Y, Ohno T, Oda H, Ikeda S, Katoh H, Ichiyanagi K, Ishikawa A, Murai A, Horio F. C3H/HeNSlc mouse with low phospholipid transfer protein expression showed dyslipidemia. Sci Rep 2023; 13:13813. [PMID: 37620514 PMCID: PMC10449841 DOI: 10.1038/s41598-023-40917-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 08/18/2023] [Indexed: 08/26/2023] Open
Abstract
High serum levels of triglycerides (TG) and low levels of high-density lipoprotein cholesterol (HDL-C) increase the risk of coronary heart disease in humans. Herein, we first reported that the C3H/HeNSlc (C3H-S) mouse, a C3H/HeN-derived substrain, is a novel model for dyslipidemia. C3H-S showed hypertriglyceridemia and low total cholesterol (TC), HDL-C, and phospholipid (PL) concentrations. To identify the gene locus causing dyslipidemia in C3H-S, we performed genetic analysis. In F2 intercrosses between C3H-S mice and strains with normal serum lipids, the locus associated with serum lipids was identified as 163-168 Mb on chromosome 2. The phospholipid transfer protein (Pltp) gene was a candidate gene within this locus. Pltp expression and serum PLTP activity were markedly lower in C3H-S mice. Pltp expression was negatively correlated with serum TG and positively correlated with serum TC and HDL-C in F2 mice. Genome sequencing analysis revealed that an endogenous retrovirus (ERV) sequence called intracisternal A particle was inserted into intron 12 of Pltp in C3H-S. These results suggest that ERV insertion within Pltp causes aberrant splicing, leading to reduced Pltp expression in C3H-S. This study demonstrated the contribution of C3H-S to our understanding of the relationship between TG, TC, and PL metabolism via PLTP.
Collapse
Affiliation(s)
- Misato Kobayashi
- Department of Nutritional Sciences, Nagoya University of Arts and Sciences, 57 Takenoyama, Iwasaki-Cho, Nisshin, Aichi, 470-0196, Japan.
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan.
| | - Fumi Kanbe
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
| | - Reika Ishii
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
| | - Hiroki Tsubouchi
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
| | - Kana Hirai
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
| | - Yuki Miyasaka
- Division of Experimental Animals, Graduate School of Medicine, Nagoya University, Aichi, Japan
| | - Tamio Ohno
- Division of Experimental Animals, Graduate School of Medicine, Nagoya University, Aichi, Japan
| | - Hiroaki Oda
- Department of Applied Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
| | - Saiko Ikeda
- Department of Nutritional Sciences, Nagoya University of Arts and Sciences, 57 Takenoyama, Iwasaki-Cho, Nisshin, Aichi, 470-0196, Japan
| | - Hirokazu Katoh
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
| | - Kenji Ichiyanagi
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
| | - Akira Ishikawa
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
| | - Atsushi Murai
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
| | - Fumihiko Horio
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Aichi, Japan
- Department of Life Studies and Environmental Science, Nagoya Women's University, Aichi, Japan
| |
Collapse
|
6
|
Duan H, Song P, Li R, Su H, He L. Attenuating lipid metabolism in atherosclerosis: The potential role of Anti-oxidative effects on low-density lipoprotein of herbal medicines. Front Pharmacol 2023; 14:1161657. [PMID: 37063287 PMCID: PMC10102431 DOI: 10.3389/fphar.2023.1161657] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 03/22/2023] [Indexed: 04/03/2023] Open
Abstract
Atherosclerosis (AS) is a multifactorial chronic disease with great harm to the health of human being, which is a basic pathogenesis of many cardiovascular diseases and ultimately threatens human life. Abnormal blood lipid level is one of the most common diagnostic indicators of AS in clinic, and lipid metabolism disorder is often observed in patients with AS. Cholesterol is an important lipid in the human body, which is of great significance for maintaining normal life activities. Generally, cholesterol is transported to peripheral tissues by low-density lipoprotein (LDL), and then transported to the liver by high-density lipoprotein (HDL) via its cholesterol reverse transport function, and finally discharged. Under oxidative stress condition, LDL is commonly oxidized to the form ox-LDL, which is ingested by macrophages in large quantities and further forms foam cells, disrupting the normal metabolic process of cholesterol. Importantly, the foam cells are involved in forming atherosclerotic plaques, whose rupture may lead to ischemic heart disease or stroke. Furthermore, ox-LDL could also promote the development of AS by damaging vascular endothelium, promoting the migration and proliferation of smooth muscle cells, and activating platelets. Therefore, inhibiting LDL oxidation may be an effective way to improve lipid metabolism and prevent AS. In recent years, increasing studies have shown that herbal medicines have great potentiality in inhibiting LDL oxidation and reducing ox-LDL induced foam cell formation. Accordingly, this paper summarized current research on the inhibitory effects of herbal medicines against LDL oxidation and foam cell formation, and made a brief description of the role of cholesterol and LDL in lipid metabolism disorder and AS pathogenesis. Importantly, it is suggested that herbal medicines could inhibit LDL oxidation and regulate cholesterol homeostasis via downregulation of CD36 and SR-A, whereas upregulation of ABCA1 and ABCG1.
Collapse
Affiliation(s)
- Huxinyue Duan
- School of Pharmacy, School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Pan Song
- Chengdu Integrated TCM and Western Medicine Hospital, Chengdu, China
| | - Ruolan Li
- School of Pharmacy, School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Hong Su
- Chengdu Integrated TCM and Western Medicine Hospital, Chengdu, China
- *Correspondence: Hong Su, ; Lisha He,
| | - Lisha He
- School of Pharmacy, School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- *Correspondence: Hong Su, ; Lisha He,
| |
Collapse
|
7
|
Liu H, Xie H, Li C, Wang L, Chen Q, Ouyang X, Yan C. Diaporisoindole B Reduces Lipid Accumulation in THP-1 Macrophage Cells via MAPKs and PPARγ-LXRα Pathways and Promotes the Reverse Cholesterol Transport by Upregulating SR-B1 and LDLR in HepG2 Cells. JOURNAL OF NATURAL PRODUCTS 2022; 85:2769-2778. [PMID: 36399085 DOI: 10.1021/acs.jnatprod.2c00715] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Diaporisoindole B (DPB), an isoprenylisoindole alkaloid isolated from the mangrove endophytic fungus Diaporthe sp. SYSU-HQ3, has been proved to have a good anti-inflammatory activity in macrophage cells. In this study, we found that DPB was able to reduce lipid accumulation in THP-1 macrophage-derived foam cells. DPB could inhibit the lipid influx-related gene CD36 and increase the expression of lipid efflux-related genes ATP binding cassette transporter A1 (ABCA1), ATP binding cassette transporter G1 (ABCG1), and scavenger receptor B1 (SR-B1). Moreover, DPB elevated low-density lipoprotein receptor (LDLR) protein expression in HepG2 cells, which can increase the transport of LDL. Meanwhile, DPB could downregulate the expression levels of proteins related to cholesterol and fatty acid synthesis. Further study showed that DPB could activate peroxisome proliferator-activated receptor gamma (PPARγ) and inhibit mitogen-activated protein kinase (MAPK) phosphorylation. Taken together, our findings demonstrated that DPB could reduce lipid accumulation in THP-1 macrophage cells by reducing the intake of lipids and promoting the efflux of lipids and also could promote the reverse cholesterol transport (RCT) mechanism by upregulating SR-B1 and LDLR in HepG2 cells.
Collapse
Affiliation(s)
- Hongju Liu
- School of Pharmacy, Guangdong Medical University, 1 Xincheng Avenue, Dongguan 523808, People's Republic of China
| | - Huiyi Xie
- School of Pharmacy, Guangdong Medical University, 1 Xincheng Avenue, Dongguan 523808, People's Republic of China
| | - Changqun Li
- School of Pharmacy, Guangdong Medical University, 1 Xincheng Avenue, Dongguan 523808, People's Republic of China
| | - Lingling Wang
- School of Pharmacy, Guangdong Medical University, 1 Xincheng Avenue, Dongguan 523808, People's Republic of China
| | - Qiling Chen
- School of Pharmacy, Guangdong Medical University, 1 Xincheng Avenue, Dongguan 523808, People's Republic of China
| | - Xin Ouyang
- School of Pharmacy, Guangdong Medical University, 1 Xincheng Avenue, Dongguan 523808, People's Republic of China
| | - Chong Yan
- School of Pharmacy, Guangdong Medical University, 1 Xincheng Avenue, Dongguan 523808, People's Republic of China
| |
Collapse
|
8
|
Dotan I, Yang J, Ikeda J, Roth Z, Pollock-Tahiri E, Desai H, Sivasubramaniyam T, Rehal S, Rapps J, Li YZ, Le H, Farber G, Alchami E, Xiao C, Karim S, Gronda M, Saikali MF, Tirosh A, Wagner KU, Genest J, Schimmer AD, Gupta V, Minden MD, Cummins CL, Lewis GF, Robbins C, Jongstra-Bilen J, Cybulsky M, Woo M. Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux. Commun Biol 2022; 5:132. [PMID: 35169231 PMCID: PMC8847578 DOI: 10.1038/s42003-022-03078-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2020] [Accepted: 01/26/2022] [Indexed: 12/11/2022] Open
Abstract
Atherosclerosis is a chronic inflammatory condition in which macrophages play a major role. Janus kinase 2 (JAK2) is a pivotal molecule in inflammatory and metabolic signaling, and Jak2V617F activating mutation has recently been implicated with enhancing clonal hematopoiesis and atherosclerosis. To determine the essential in vivo role of macrophage (M)-Jak2 in atherosclerosis, we generate atherosclerosis-prone ApoE-null mice deficient in M-Jak2. Contrary to our expectation, these mice exhibit increased plaque burden with no differences in macrophage proliferation, recruitment or bone marrow clonal expansion. Notably, M-Jak2-deficient bone marrow derived macrophages show a significant defect in cholesterol efflux. Pharmacologic JAK2 inhibition with ruxolitinib also leads to defects in cholesterol efflux and accelerates atherosclerosis. Liver X receptor agonist abolishes the efflux defect and attenuates the accelerated atherosclerosis that occurs with M-Jak2 deficiency. Macrophages of individuals with the Jak2V617F mutation show increased efflux which is normalized when treated with a JAK2 inhibitor. Together, M-Jak2-deficiency leads to accelerated atherosclerosis primarily through defects in cholesterol efflux from macrophages.
Collapse
Affiliation(s)
- Idit Dotan
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.,Institute of Endocrinology, Beilinson Campus, Rabin Medical Center, Petach Tikva, Israel
| | - Jiaqi Yang
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Jiro Ikeda
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Ziv Roth
- Program in Cell Biology, Peter Gilgan Centre for Research and Learning, Hospital for Sick Children, Toronto, Canada
| | - Evan Pollock-Tahiri
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Harsh Desai
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | | | - Sonia Rehal
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Josh Rapps
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Yu Zhe Li
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Helen Le
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Gedaliah Farber
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Edouard Alchami
- Department of Immunology, University of Toronto, Toronto, Canada
| | - Changting Xiao
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Saraf Karim
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Marcela Gronda
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Michael F Saikali
- Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada
| | - Amit Tirosh
- Endocrine Cancer Genomics Center, Sheba Medical Center, Tel Hashomer, Israel
| | - Kay-Uwe Wagner
- Department of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
| | - Jacques Genest
- Research Institute of the McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada
| | - Aaron D Schimmer
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Vikas Gupta
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Mark D Minden
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Carolyn L Cummins
- Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada
| | - Gary F Lewis
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada
| | - Clinton Robbins
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.,Department of Immunology, University of Toronto, Toronto, Canada
| | - Jenny Jongstra-Bilen
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.,Department of Immunology, University of Toronto, Toronto, Canada
| | - Myron Cybulsky
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.,Department of Immunology, University of Toronto, Toronto, Canada
| | - Minna Woo
- Toronto General Hospital Research Institute, University Health Network, Toronto, Canada. .,Department of Immunology, University of Toronto, Toronto, Canada. .,Division of Endocrinology and Metabolism, Department of Medicine, University Health Network and Sinai Health System, University of Toronto, Toronto, Canada.
| |
Collapse
|
9
|
HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use? Int J Pept Res Ther 2022. [DOI: 10.1007/s10989-021-10352-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
10
|
Immuno-regenerative biomaterials for in situ cardiovascular tissue engineering - Do patient characteristics warrant precision engineering? Adv Drug Deliv Rev 2021; 178:113960. [PMID: 34481036 DOI: 10.1016/j.addr.2021.113960] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 08/20/2021] [Accepted: 08/30/2021] [Indexed: 02/07/2023]
Abstract
In situ tissue engineering using bioresorbable material implants - or scaffolds - that harness the patient's immune response while guiding neotissue formation at the site of implantation is emerging as a novel therapy to regenerate human tissues. For the cardiovascular system, the use of such implants, like blood vessels and heart valves, is gradually entering the stage of clinical translation. This opens up the question if and to what extent patient characteristics influence tissue outcomes, necessitating the precision engineering of scaffolds to guide patient-specific neo-tissue formation. Because of the current scarcity of human in vivo data, herein we review and evaluate in vitro and preclinical investigations to predict the potential role of patient-specific parameters like sex, age, ethnicity, hemodynamics, and a multifactorial disease profile, with special emphasis on their contribution to the inflammation-driven processes of in situ tissue engineering. We conclude that patient-specific conditions have a strong impact on key aspects of in situ cardiovascular tissue engineering, including inflammation, hemodynamic conditions, scaffold resorption, and tissue remodeling capacity, suggesting that a tailored approach may be required to engineer immuno-regenerative biomaterials for safe and predictive clinical applicability.
Collapse
|
11
|
Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel. PLoS Negl Trop Dis 2021; 15:e0009714. [PMID: 34424905 PMCID: PMC8425554 DOI: 10.1371/journal.pntd.0009714] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 09/08/2021] [Accepted: 08/06/2021] [Indexed: 12/26/2022] Open
Abstract
Background Pulmonary sequelae (PS) in patients with chronic paracoccidioidomycosis (PCM) typically include pulmonary fibrosis and emphysema. Knowledge of the molecular pathways involved in PS of PCM is required for treatment and biomarker identification. Methodology/Principal findings This non-concurrent cohort study included 29 patients with pulmonary PCM that were followed before and after treatment. From this group, 17 patients evolved to mild/ moderate PS and 12 evolved severe PS. Sera from patients were evaluated before treatment and at clinical cure, serological cure, and apparent cure. A nanoACQUITY UPLC-Xevo QT MS system and PLGS software were used to identify serum differentially expressed proteins, data are available via ProteomeXchange with identifier PXD026906. Serum differentially expressed proteins were then categorized using Cytoscape software and the Reactome pathway database. Seventy-two differentially expressed serum proteins were identified in patients with severe PS compared with patients with mild/moderate PS. Most proteins altered in severe PS were involved in wound healing, inflammatory response, and oxygen transport pathways. Before treatment and at clinical cure, signaling proteins participating in wound healing, complement cascade, cholesterol transport and retinoid metabolism pathways were downregulated in patients with severe PS, whereas signaling proteins in gluconeogenesis and gas exchange pathways were upregulated. At serological cure, the pattern of protein expression reversed. At apparent cure pathways related with tissue repair (fibrosis) became downregulated, and pathway related oxygen transport became upregulated. Additionally, we identified 15 proteins as candidate biomarkers for severe PS. Conclusions/Significance Development of severe PS is related to increased expression of proteins involved in glycolytic pathway and oxygen exchange), indicative of the greater cellular activity and replication associated with early dysregulation of wound healing and aberrant tissue repair. Our findings provide new targets to study mechanisms of PS in PCM, as well as potential biomarkers. Pulmonary fibrosis is the main sequel of paracoccidioidomycosis (PCM), a fungal disease that affects mainly men, rural workers. The development of pulmonary fibrosis is complex and involves several mechanisms that culminate in aberrant collagen production and deposition in the lungs making it became stiff and blocking the air passages. These changes lead to difficulty in breathing and in PCM patients dyspnea in response to high or low levels of exertion is common. Therefore, these patients show incapacity to work and the decreased quality of life. With the possibility of identifying some marker, for example, it could help the indication of respiratory physiotherapy, professional rehabilitation, or therapeutic intervention. This is the first study to examine the pulmonary sequelae (PS) in patients with paracoccidioidomycosis using an approach combining proteomics with bioinformatics. Here, we identify the specific proteome pattern found in PCM patients with severe sequelae that distinguishes these patients from that with mild/moderate sequelae. Our results showed that time points immediately before treatment and at clinical cure are key moments at which PS can progress to severe PS due a dysregulation in wound healing with consequent delayed in the healing processes resulting in an aberrant scar. As such, we suggest that the prognoses for severe PS should be considered as soon as possible and as early as diagnosis of PCM. Furthermore, we used proteomics to identify possible serum biomarkers with which to predict the likely development of severe PS, to be validated in future studies.
Collapse
|
12
|
Wang X, Ren S, Yang X, Masoudi A, Xue X, Li M, Li H, Zhang X, Wang H, Liu J. Exploration of Serum Marker Proteins in Mice Induced by Babesia microti Infection Using a Quantitative Proteomic Approach. Protein J 2021; 40:119-130. [PMID: 33387247 DOI: 10.1007/s10930-020-09952-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/16/2020] [Indexed: 11/29/2022]
Abstract
Babesia microti is a protozoan that mainly parasitizes rodent and human erythrocytes. B. microti infection can result in changes in the expression levels of various proteins in the host serum. To explore the mechanism underlying the regulation of serum proteins by the host during B. microti infection, this study used a data-independent acquisition (DIA) quantitative proteomic approach to perform comprehensive quantitative proteomic analysis on the serum of B. microti-infected mice. We identified and analysed 333 serum proteins during the infectious stage and recovery stage within 30 days of infection by B. microti in mice. Through quantitative analysis, we found 57 proteins differentially expressed in the infection stage and 69 proteins differentially expressed in the recovery stage. Bioinformatics analysis revealed that these differentially expressed proteins were mainly concentrated in organelles, cell parts, and extracellular regions that are mainly involved in immune system, metabolic, and cellular processes. Additionally, the differentially expressed proteins mainly had catalytic activity. Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis showed that many of the differentially expressed proteins participate in the complement and coagulation cascade reaction, including complement C3, complement FP, and coagulation factor XII. The results of this study can provide more information for the selection of biomarkers for the early clinical monitoring of babesiosis and help in the treatment of babesiosis.
Collapse
Affiliation(s)
- Xiaoshuang Wang
- Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, 050024, Hebei, People's Republic of China
| | - Shuguang Ren
- Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, 050024, Hebei, People's Republic of China.,The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, People's Republic of China
| | - Xiaohong Yang
- Department of Pathogenic Biology, College of Basic Medicine, Hebei Medical University, Shijiazhuang, 050017, Hebei, People's Republic of China.,State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730046, Gansu, People's Republic of China
| | - Abolfazl Masoudi
- Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, 050024, Hebei, People's Republic of China
| | - Xiaomin Xue
- Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, 050024, Hebei, People's Republic of China
| | - Mengxue Li
- Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, 050024, Hebei, People's Republic of China
| | - Hongxia Li
- Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, 050024, Hebei, People's Republic of China
| | - Xiaojing Zhang
- Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, 050024, Hebei, People's Republic of China
| | - Hui Wang
- Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, 050024, Hebei, People's Republic of China. .,Hebei Normal University, 20 nanerhuan east road, Shijiazhuang, Hebei, People's Republic of China.
| | - Jingze Liu
- Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, 050024, Hebei, People's Republic of China. .,Hebei Normal University, 20 nanerhuan east road, Shijiazhuang, Hebei, People's Republic of China.
| |
Collapse
|
13
|
Bannon CA, Gallacher D, Hanson P, Randeva HS, Weickert MO, Barber TM. Systematic review and meta-analysis of the metabolic effects of modified-release hydrocortisone versus standard glucocorticoid replacement therapy in adults with adrenal insufficiency. Clin Endocrinol (Oxf) 2020; 93:637-651. [PMID: 32621327 DOI: 10.1111/cen.14275] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 06/01/2020] [Accepted: 06/22/2020] [Indexed: 12/29/2022]
Abstract
CONTEXT Published studies exploring the metabolic effects of Modified-Release Hydrocortisone (MR-HC) replacement in patients with adrenal insufficiency (AI). OBJECTIVE To compare metabolic effects of MR-HC with Standard Glucocorticoid (SG) replacement in adults with AI. Randomized control trials (RCTs) were meta-analysed; non-RCT studies described narratively with critical appraisal. DATA SOURCES PubMed/Medline, EMBASE, CINAHL and CENTRAL were searched to identify relevant articles, published before Aug 2019. STUDY SELECTION All study types that reported metabolic profile (including anthropometric, glucose and lipid-related parameters), on patients switched from SG to MR-HC replacement. Following independent screening from two reviewers, 390 studies were identified, of which 9 studies were included for review (RCT, n = 2; non-RCT, n = 7). DATA EXTRACTION Two independent reviewers assessed each paper for bias and data extraction. RESULTS Meta-analysis from RCTs (n = 2), 104 patients were switched from SG to MR-HC replacement. Combining treatment effects, at 3-months post-therapy switch there was significant reduction in body weight (-0.82 kg; 95% CI: -1.24 kg to -0.40 kg; P < .001) and HbA1c (-0.13%; 95% CI: -0.214% to -0.045%; P = .003). In the sub-group with Diabetes Mellitus (DM), reduction in HbA1C was more pronounced (-0.52%; 95% CI: -0.82% to -0.23%; P < .001). Non-RCT studies showed improved anthropometric measures and glucose metabolism up to 48-months following switch from SG to MR-HC replacement. CONCLUSIONS In adults with AI, replacement with MR-HC associates with significant improvements in anthropometric measurements and HbA1c compared with SG replacement, particularly those with DM.
Collapse
Affiliation(s)
- Christopher A Bannon
- Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK
- Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University Hospitals Coventry and Warwickshire, Coventry, UK
| | - Daniel Gallacher
- Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK
| | - Petra Hanson
- Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK
- Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University Hospitals Coventry and Warwickshire, Coventry, UK
| | - Harpal S Randeva
- Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK
- Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University Hospitals Coventry and Warwickshire, Coventry, UK
- Centre of Applied Biological & Exercise Sciences, Faculty of Health & Life Sciences, Coventry University, Coventry, UK
| | - Martin O Weickert
- Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK
- Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University Hospitals Coventry and Warwickshire, Coventry, UK
- Centre of Applied Biological & Exercise Sciences, Faculty of Health & Life Sciences, Coventry University, Coventry, UK
| | - Thomas M Barber
- Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK
- Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University Hospitals Coventry and Warwickshire, Coventry, UK
| |
Collapse
|
14
|
An Increased Plasma Level of ApoCIII-Rich Electronegative High-Density Lipoprotein May Contribute to Cognitive Impairment in Alzheimer's Disease. Biomedicines 2020; 8:biomedicines8120542. [PMID: 33256187 PMCID: PMC7761422 DOI: 10.3390/biomedicines8120542] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 11/24/2020] [Accepted: 11/24/2020] [Indexed: 02/02/2023] Open
Abstract
High-density lipoprotein (HDL) plays a vital role in lipid metabolism and anti-inflammatory activities; a dysfunctional HDL impairs cholesterol efflux pathways. To understand HDL's role in patients with Alzheimer's disease (AD), we analyzed the chemical properties and function. HDL from AD patients (AD-HDL) was separated into five subfractions, H1-H5, using fast-protein liquid chromatography equipped with an anion-exchange column. Subfraction H5, defined as the most electronegative HDL, was increased 5.5-fold in AD-HDL (23.48 ± 17.83%) in comparison with the control HDL (4.24 ± 3.22%). By liquid chromatography mass spectrometry (LC/MSE), AD-HDL showed that the level of apolipoprotein (apo)CIII was elevated but sphingosine-1-phosphate (S1P)-associated apoM and anti-oxidative paraoxonase 1 (PON1) were reduced. AD-HDL showed a lower cholesterol efflux capacity that was associated with the post-translational oxidation of apoAI. Exposure of murine macrophage cell line, RAW 264.7, to AD-HDL induced a vibrant expression of ganglioside GM1 in colocalization with apoCIII on lipid rafts alongside a concomitant increase of tumor necrosis factor-α (TNF-α) detectable in the cultured medium. In conclusion, AD-HDL had a higher proportion of H5, an apoCIII-rich electronegative HDL subfraction. The associated increase in pro-inflammatory (apoCIII, TNF-α) components might favor Amyloid β assembly and neural inflammation. A compromised cholesterol efflux capacity of AD-HDL may also contribute to cognitive impairment.
Collapse
|
15
|
Piconi S, Foschi A, Malagoli A, Carli F, Zona S, Milic J, Ricci ED, Rizzardini G, Guaraldi G. Impact of prolonged maraviroc treatment on non-AIDS-related comorbidities in HIV-positive patients: a retrospective cohort study. J Antimicrob Chemother 2020; 74:2723-2731. [PMID: 31139818 DOI: 10.1093/jac/dkz227] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 04/29/2019] [Accepted: 04/29/2019] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVES This retrospective study evaluates the effect of maraviroc, the first CCR5 receptor antagonist, on non-AIDS-related comorbidity incidence and its impact on inflammatory and lipid parameters. METHODS Seventy-four HIV patients on maraviroc treatment were compared with 312 patients never exposed to maraviroc (matched for sex, age and CD4 nadir). RESULTS At baseline (T0), maraviroc patients presented a longer duration of HIV infection, a higher prevalence of comorbidities and a greater frequency of polypharmacy. Non-AIDS-defining disease incidence was lower in the maraviroc group than in the non-maraviroc group (without achieving statistical significance). Except triglycerides (TGL), which dropped only in the maraviroc group, inflammatory and immunological parameters did not significantly change in either group by the end of the study period (T3). At T3, high-sensitivity C-reactive protein (hsCRP) and high-density lipoprotein were inversely correlated in both groups (Spearman's rho: maraviroc -0.30, P = 0.05; non-maraviroc -0.23, P = 0.0003). Only in the non-maraviroc group was the positive correlation between hsCRP and lipids observed both at T0 (hsCRP/low-density lipoprotein (LDL) +0.17, P = 0.004; hsCRP/total cholesterol +0.20, P = 0.0007; hsCRP/TGL +0.12, P = 0.04) and T3 (hsCRP/LDL +0.26, P < 0.0001; hsCRP/total cholesterol +0.24, P = 0.0001; hsCRP/TGL +0.15, P = 0.02). These correlations were not found in the maraviroc group. A significant positive correlation was found at T0 and at T3 between hsCRP and D-dimer in both groups (maraviroc: T0 +0.46, P = 0.0007; T3 +0.41, P = 0.006; non-maraviroc: T0 +0.17, P = 0.02; T3: +0.17, P = 0.017). CONCLUSIONS These data suggest a possible protective role of maraviroc in the incidence of non-AIDS-related comorbidities in a population with longer-lasting infection and allow us to hypothesize its role in the modulation of lipid-dependent inflammation.
Collapse
Affiliation(s)
- Stefania Piconi
- First Infectious Diseases Department, Ospedale Luigi Sacco, Milano, Italy
| | - Antonella Foschi
- First Infectious Diseases Department, Ospedale Luigi Sacco, Milano, Italy
| | - Andrea Malagoli
- Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy
| | - Federica Carli
- HIV Metabolic Clinic, Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy
| | - Stefano Zona
- HIV Metabolic Clinic, Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy
| | - Jovana Milic
- HIV Metabolic Clinic, Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy
| | | | | | - Giovanni Guaraldi
- HIV Metabolic Clinic, Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
16
|
Baldan-Martin M, Martin-Rojas T, Corbacho-Alonso N, Lopez JA, Sastre-Oliva T, Gil-Dones F, Vazquez J, Arevalo JM, Mourino-Alvarez L, Barderas MG. Comprehensive Proteomic Profiling of Pressure Ulcers in Patients with Spinal Cord Injury Identifies a Specific Protein Pattern of Pathology. Adv Wound Care (New Rochelle) 2020; 9:277-294. [PMID: 32226651 PMCID: PMC7099418 DOI: 10.1089/wound.2019.0968] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2019] [Accepted: 05/10/2019] [Indexed: 12/26/2022] Open
Abstract
Objective: Severe pressure ulcers (PUs) do not respond to conservative wound therapy and need surgical repair. To better understand the pathogenesis and to advance on new therapeutic options, we focused on the proteomic analysis of PU, which offers substantial opportunities to identify significant changes in protein abundance during the course of PU formation in an unbiased manner. Approach: To better define the protein pattern of this pathology, we performed a proteomic approach in which we compare severe PU tissue from spinal cord injury (SCI) patients with control tissue from the same patients. Results: We found 76 proteins with difference in abundance. Of these, 10 proteins were verified as proteins that define the pathology: antithrombin-III, alpha-1-antitrypsin, kininogen-1, alpha-2-macroglobulin, fibronectin, apolipoprotein A-I, collagen alpha-1 (XII) chain, haptoglobin, apolipoprotein B-100, and complement factor B. Innovation: This is the first study to analyze differential abundance protein of PU tissue from SCI patients using high-throughput protein identification and quantification by tandem mass tags followed by liquid chromatography tandem mass spectrometry. Conclusion: Differential abundance proteins are mainly involved in tissue regeneration. These proteins might be considered as future therapeutic options to enhance the physiological response and permit cellular repair of damaged tissue.
Collapse
Affiliation(s)
- Montserrat Baldan-Martin
- Department of Vascular Physiopathology, National Hospital for Paraplegics (HNP), SESCAM, Toledo, Spain
| | - Tatiana Martin-Rojas
- Department of Vascular Physiopathology, National Hospital for Paraplegics (HNP), SESCAM, Toledo, Spain
| | - Nerea Corbacho-Alonso
- Department of Vascular Physiopathology, National Hospital for Paraplegics (HNP), SESCAM, Toledo, Spain
| | - Juan Antonio Lopez
- Department of Plastic Surgery, National Hospital for Paraplegics (HNP), SESCAM, Toledo, Spain
| | - Tamara Sastre-Oliva
- Department of Vascular Physiopathology, National Hospital for Paraplegics (HNP), SESCAM, Toledo, Spain
| | - Felix Gil-Dones
- Department of Vascular Physiopathology, National Hospital for Paraplegics (HNP), SESCAM, Toledo, Spain
| | - Jesus Vazquez
- Department of Plastic Surgery, National Hospital for Paraplegics (HNP), SESCAM, Toledo, Spain
| | | | - Laura Mourino-Alvarez
- Department of Vascular Physiopathology, National Hospital for Paraplegics (HNP), SESCAM, Toledo, Spain
| | - Maria G. Barderas
- Department of Vascular Physiopathology, National Hospital for Paraplegics (HNP), SESCAM, Toledo, Spain
| |
Collapse
|
17
|
Anthocyanin supplementation at different doses improves cholesterol efflux capacity in subjects with dyslipidemia-a randomized controlled trial. Eur J Clin Nutr 2020; 75:345-354. [PMID: 32317748 DOI: 10.1038/s41430-020-0609-4] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 03/04/2020] [Accepted: 03/06/2020] [Indexed: 01/11/2023]
Abstract
BACKGROUND/OBJECTIVES Numerous clinical trials have confirmed that supplementation with purified anthocyanins has favorable effects on metabolic diseases, but the dose-response of dyslipidemia to anthocyanin supplementation remains unclear. This study aimed to investigate the effect of anthocyanin supplementation in different doses on lipid profile. SUBJECTS/METHODS We randomly assigned 176 dyslipidemic subjects aged 35-70 to three purified anthocyanin groups (40 mg/day, n = 45; 80 mg/day, n = 42; 320 mg/day, n = 43) and a placebo group (n = 46). Anthropometric parameters, serum lipid profiles, and cholesterol efflux capacity (CEC) were measured at baseline, and at the end of 6 and 12 weeks. RESULTS After 12 weeks of supplementation, significant differences in CEC (P = 0.033), high-density lipoprotein cholesterol (HDL-C) (P = 0.043), and apolipoprotein A-I (ApoA-I) (P = 0.022) were observed between four groups. Compared with placebo, 320 mg/day anthocyanin significantly increased CEC (35.8%, 95% CI: 11.5-60.2%; P = 0.004), HDL-C (0.07 mmol/L, 95% CI: 0.01-0.14; P = 0.003), and ApoA-I (0.07 g/L, 95% CI: 0.01-0.12; P = 0.008). Linear trend analysis showed that anthocyanin supplementation has a strong dose-response relationship with CEC (P = 0.002), HDL-C (P = 0.038), and ApoA-I (P = 0.023). Moreover, the enhancement of CEC showed positive correlations with the increase in HDL-C (r = 0.215, P < 0.01) and APOA-I (r = 0.327, P < 0.01). CONCLUSIONS Anthocyanin supplementation at 0-320 mg/day for 12 weeks enhances CEC in a dose-response manner in dyslipidemic subjects. Anthocyanin supplementation doses of 80-320 mg/day can improve serum HDL-C levels and HDL-induced CEC.
Collapse
|
18
|
Zamanian-Daryoush M, Gogonea V, DiDonato AJ, Buffa JA, Choucair I, Levison BS, Hughes RA, Ellington AD, Huang Y, Li XS, DiDonato JA, Hazen SL. Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis. J Biol Chem 2020; 295:4836-4848. [PMID: 32098873 DOI: 10.1074/jbc.ra119.012092] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Revised: 02/13/2020] [Indexed: 12/20/2022] Open
Abstract
Apolipoprotein A-I (apoA-I) is the major protein constituent of high-density lipoprotein (HDL) and a target of myeloperoxidase-dependent oxidation in the artery wall. In atherosclerotic lesions, apoA-I exhibits marked oxidative modifications at multiple sites, including Trp72 Site-specific mutagenesis studies have suggested, but have not conclusively shown, that oxidative modification of Trp72 of apoA-I impairs many atheroprotective properties of this lipoprotein. Herein, we used genetic code expansion technology with an engineered Saccharomyces cerevisiae tryptophanyl tRNA-synthetase (Trp-RS):suppressor tRNA pair to insert the noncanonical amino acid 5-hydroxytryptophan (5-OHTrp) at position 72 in recombinant human apoA-I and confirmed site-specific incorporation utilizing MS. In functional characterization studies, 5-OHTrp72 apoA-I (compared with WT apoA-I) exhibited reduced ABC subfamily A member 1 (ABCA1)-dependent cholesterol acceptor activity in vitro (41.73 ± 6.57% inhibition; p < 0.01). Additionally, 5-OHTrp72 apoA-I displayed increased activation and stabilization of paraoxonase 1 (PON1) activity (μmol/min/mg) when compared with WT apoA-I and comparable PON1 activation/stabilization compared with reconstituted HDL (WT apoA-I, 1.92 ± 0.04; 5-OHTrp72 apoA-I, 2.35 ± 0.0; and HDL, 2.33 ± 0.1; p < 0.001, p < 0.001, and p < 0.001, respectively). Following injection into apoA-I-deficient mice, 5-OHTrp72 apoA-I reached plasma levels comparable with those of native apoA-I yet exhibited significantly reduced (48%; p < 0.01) lipidation and evidence of HDL biogenesis. Collectively, these findings unequivocally reveal that site-specific oxidative modification of apoA-I via 5-OHTrp at Trp72 impairs cholesterol efflux and the rate-limiting step of HDL biogenesis both in vitro and in vivo.
Collapse
Affiliation(s)
- Maryam Zamanian-Daryoush
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195.,Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195
| | - Valentin Gogonea
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195.,Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195.,Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115
| | - Anthony J DiDonato
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195.,Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195
| | - Jennifer A Buffa
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195.,Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195
| | - Ibrahim Choucair
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195.,Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195.,Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115
| | - Bruce S Levison
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195
| | - Randall A Hughes
- United States Army Research Laboratory South, University of Texas, Austin, Texas 78712
| | - Andrew D Ellington
- Center for Systems and Synthetic Biology, University of Texas, Austin, Texas 78712
| | - Ying Huang
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195.,Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195
| | - Xinmin S Li
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195.,Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195
| | - Joseph A DiDonato
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195.,Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195
| | - Stanley L Hazen
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195 .,Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, Ohio 44195.,Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio 44195
| |
Collapse
|
19
|
Li X, Guan B, Wang Y, Tse G, Zou F, Khalid BW, Xia Y, Wu S, Sun J. Association between high-density lipoprotein cholesterol and all-cause mortality in the general population of northern China. Sci Rep 2019; 9:14426. [PMID: 31594968 PMCID: PMC6783426 DOI: 10.1038/s41598-019-50924-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Accepted: 09/12/2019] [Indexed: 12/20/2022] Open
Abstract
Recent studies proposed reasonable doubts about the good prognosis of very high levels of high-density lipoprotein cholesterol (HDL-c). We aimed to investigate the association between HDL-c levels and all-cause mortality using data from an observational cohort study in northern China from 2006 to 2015. The study population was stratified into six groups by HDL-c levels in mg/dl (<40, 40–49, 50–59, 60–69, 70–79, ≥80). Cox hazards regression models were used to estimate the association between HDL-c levels and all-cause mortality. In total, 100,070 participants (aged 51.9 ± 12.7 years) were included in the current analysis. During a mean follow-up of 8.76 years, 7,362 deaths were identified (mortality rate, 8.40 per 1000 person-years). There was a significant interaction effect between age and HDL-c levels (P for interaction < 0.001). Among individuals aged 65 and older, no significant association was found between HDL-c levels and total mortality. In contrast, HDL-c levels showed a U-shaped relationship with all-cause mortality in younger participants (<65 years old), and very high HDL-c levels (≥80 mg/dl) were independently associated with increased total mortality risk compared with the reference level (60 to 69 mg/dl). These findings suggest that very high HDL-c levels may not represent a good prognosis, especially in younger individuals.
Collapse
Affiliation(s)
- Xintao Li
- Department of Cardiology, The First People's Hospital of Changzhou, Changzhou, 213000, China
| | - Bo Guan
- Department of Cardiology, The First People's Hospital of Changzhou, Changzhou, 213000, China
| | - Yanjun Wang
- Department of Cardiology, The First People's Hospital of Changzhou, Changzhou, 213000, China
| | - Gary Tse
- Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, 999077, China.,Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China
| | - Fuquan Zou
- Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China
| | - Bin Waleed Khalid
- Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China
| | - Yunlong Xia
- Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China
| | - Shouling Wu
- Department of Cardiology, Kailuan General Hospital, Tangshan, 063000, China.
| | - Jianhui Sun
- Department of Cardiology, The First People's Hospital of Changzhou, Changzhou, 213000, China.
| |
Collapse
|
20
|
Farag AGA, Badr EA, Eltorgoman AMA, Assar MF, Elshafey EN, Tayel NR, Aboutaleb HE. Role of 11β HSD 1, rs12086634, and rs846910 single-nucleotide polymorphisms in metabolic-related skin diseases: a clinical, biochemical, and genetic study. Clin Cosmet Investig Dermatol 2019; 12:91-102. [PMID: 30774405 PMCID: PMC6350638 DOI: 10.2147/ccid.s193156] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Background 11β HSD1 generates cortisol from cortisone. 11β HSD1 single-nucleotide polymorphism (SNP) was associated with metabolic syndrome (MeTS). Although the relation of acne vulgaris (AV) and skin tags (STs) with MeTS has been reported, the relationship between 11β HSD 1 SNP and cortisol activity in those patients has not studied till now. Aims To investigate, two 11β-HSD1 SNPs (rs846910 and rs12086634), serum lipid profile and cortisol levels in patients with AV and STs in an Egyptian population. Patients and methods This case–control study was performed on 50 patients having STs and 50 complaining of AV and 50 sex- and age-matched controls. We searched for serum lipid profile, cortisol levels, and 11β-HSD1 rs846910 and rs12086634 SNPs using real time-PCR. Results Compared to controls,11β-HSD1 rs846910 GA genotype carriers had significantly higher risks for developing AV and STs by 3.4- and 4.9-fold, respectively, and its A allele increases these risks by 3.1 and 4.4 times, respectively. Also, 11β-HSD1 rs12086634 TG genotype increases the risk of AV by 3.2-fold, as well as STs by 3.5-fold, and its G allele increases the risk of AV by 3.2-fold and STs by 7-fold. In AV and ST patients, rs846910 GA genotype demonstrated significant associations with elevated body mass index (BMI), and cholesterol, low density lipoprotein (LDL), cortisol, and decreased high density lipoprotein serum levels, respectively. However, rs12086634 GG genotype was significantly associated with increased BMI, cholesterol, and LDL serum levels in patients with AV and STs, in addition to the number of STs and serum cortisol levels in ST patients. Conclusion 11β-HSD1 rs846910 and rs12086634 gene polymorphisms may contribute to AV and STs pathogenesis, that may be mediated through enhancing the enzymatic activity (increasing cortisol levels). AV and STs are associated with obesity and atherogenic lipid profile. Diagnosis of AV and STs may play a role in early detection of the MeTS.
Collapse
Affiliation(s)
- Azza Gaber Antar Farag
- Department of Dermatology, Andrology and STDs, Faculty of Medicine, Menoufia University, Shibin El Kom, Egypt,
| | - Eman Ae Badr
- Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Shibin El Kom, Egypt
| | | | - Mohamed Fa Assar
- Department of Chemistry, Biochemistry Division, Faculty of Science, Menoufia University, Shibin El Kom, Egypt
| | - Eman N Elshafey
- Department of Dermatology, Andrology and STDs, Faculty of Medicine, Menoufia University, Shibin El Kom, Egypt, .,Department of Chemistry, Biochemistry Division, Faculty of Science, Menoufia University, Shibin El Kom, Egypt
| | - Nermin Reda Tayel
- Department of Molecular Diagnostics and Therapeutics, Genetic Engineering Biotechnology Research Institute, Sadat City, Egypt
| | - Hossam Ea Aboutaleb
- Department of Chemistry, Biochemistry Division, Faculty of Science, Menoufia University, Shibin El Kom, Egypt
| |
Collapse
|
21
|
The Acute Effects of Cigarette Smoking on the Functional State of High Density Lipoprotein. Am J Med Sci 2018; 356:374-381. [DOI: 10.1016/j.amjms.2018.07.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 06/27/2018] [Accepted: 07/12/2018] [Indexed: 02/07/2023]
|
22
|
Abstract
Foam cells are lipid-loaded macrophages and neutrophils that are generated from a massive uptake of oxidized lipid. Foam cells are a pathological hallmark of atherosclerosis, and have also been found in acne lesions. The same pathological changes determine the common pathogenesis. According to the pathological function of foam cells in these lesions, we put forward a viewpoint on the pathogenesis of acne and atherosclerotic plaques.
Collapse
|
23
|
Zhao ZW, Zhang M, Chen LY, Gong D, Xia XD, Yu XH, Wang SQ, Ou X, Dai XY, Zheng XL, Zhang DW, Tang CK. Heat shock protein 70 accelerates atherosclerosis by downregulating the expression of ABCA1 and ABCG1 through the JNK/Elk-1 pathway. Biochim Biophys Acta Mol Cell Biol Lipids 2018; 1863:806-822. [DOI: 10.1016/j.bbalip.2018.04.011] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2017] [Revised: 03/30/2018] [Accepted: 04/15/2018] [Indexed: 12/14/2022]
|
24
|
Zhang M, Zhao GJ, Yao F, Xia XD, Gong D, Zhao ZW, Chen LY, Zheng XL, Tang XE, Tang CK. AIBP reduces atherosclerosis by promoting reverse cholesterol transport and ameliorating inflammation in apoE −/− mice. Atherosclerosis 2018; 273:122-130. [DOI: 10.1016/j.atherosclerosis.2018.03.010] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 02/22/2018] [Accepted: 03/06/2018] [Indexed: 01/09/2023]
|
25
|
Takiguchi S, Ayaori M, Yakushiji E, Nishida T, Nakaya K, Sasaki M, Iizuka M, Uto-Kondo H, Terao Y, Yogo M, Komatsu T, Ogura M, Ikewaki K. Hepatic Overexpression of Endothelial Lipase Lowers High-Density Lipoprotein but Maintains Reverse Cholesterol Transport in Mice: Role of Scavenger Receptor Class B Type I/ATP-Binding Cassette Transporter A1-Dependent Pathways. Arterioscler Thromb Vasc Biol 2018; 38:1454-1467. [PMID: 29748333 PMCID: PMC6039415 DOI: 10.1161/atvbaha.118.311056] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 04/11/2018] [Indexed: 01/06/2023]
Abstract
Supplemental Digital Content is available in the text. Objective— Reverse cholesterol transport (RCT) is a major mechanism by which HDL (high-density lipoprotein) protects against atherosclerosis. Endothelial lipase (EL) reportedly reduces HDL levels, which, in theory, would increase atherosclerosis. However, it remains unclear whether EL affects RCT in vivo. Approach and Results— Adenoviral vectors expressing EL or luciferase were intravenously injected into mice, and a macrophage RCT assay was performed. As expected, hepatic EL overexpression markedly reduced HDL levels. In parallel, plasma 3H-cholesterol counts from the EL-expressing mice decreased by 85% compared with control. Surprisingly, there was no difference in fecal 3H-cholesterol excretion between the groups. Kinetic studies revealed increased catabolism/hepatic uptake of 3HDL-cholesteryl ether, resulting in no change in fecal HDL-cholesteryl ester excretion in the mice. To explore underlying mechanisms for the preservation of RCT despite low HDL levels in the EL-expressing mice, we investigated the effects of hepatic SR-BI (scavenger receptor class B type I) knockdown. RCT assay revealed that knockdown of SR-BI alone reduced fecal excretion of macrophage-derived 3H-cholesterol. Interestingly, hepatic EL overexpression under SR-BI inhibition further attenuated fecal tracer counts as compared with control. Finally, we observed that EL overexpression enhanced in vivo RCT under pharmacological inhibition of hepatic ABCA1 (ATP-binding cassette transporter A1) by probucol. Conclusions— Hepatic EL expression compensates for reduced macrophage-derived cholesterol efflux to plasma because of low HDL levels by promoting cholesterol excretion to bile/feces via an SR-BI pathway, maintaining overall RCT in vivo. In contrast, EL-modified HDL might negatively regulate RCT via hepatic ABCA1. Despite extreme hypoalphalipoproteinemia, RCT is maintained in EL-expressing mice via SR-BI/ABCA1-dependent pathways.
Collapse
Affiliation(s)
- Shunichi Takiguchi
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Makoto Ayaori
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Emi Yakushiji
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Takafumi Nishida
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Kazuhiro Nakaya
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Makoto Sasaki
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Maki Iizuka
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Harumi Uto-Kondo
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Yoshio Terao
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Makiko Yogo
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Tomohiro Komatsu
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| | - Masatsune Ogura
- Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center, Osaka, Japan (M.O.)
| | - Katsunori Ikewaki
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
| |
Collapse
|
26
|
Park JS, Cha KS, Lee HW, Oh JH, Choi JH, Lee HC, Hong TJ, Jeong MH, Chae SC, Kim YJ. Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction. Cardiol J 2018; 26:176-185. [PMID: 29512093 PMCID: PMC8086654 DOI: 10.5603/cj.a2018.0020] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Revised: 03/02/2018] [Accepted: 08/11/2016] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND It is unclear whether high-density lipoprotein cholesterol (HDL-C) level predicts cardiovascular events and has a protective effect in patients with acute myocardial infarction (AMI) undergo- ing percutaneous coronary intervention (PCI) and statin treatment. METHODS A total of 15,290 AMI patients receiving statins were selected from the Korean Myocardial Infarction Registry. Baseline HDL-C level was used to identify patients with low (group A), normal (group B), and high (group C) HDL-C levels according to the Adult Treatment Panel III criteria. Clinical outcomes were compared in propensity-adjusted and matched cohorts. The primary endpoint was a composite of cardiovascular death and recurrent myocardial infarction. RESULTS At the median follow-up of 11.5 months, the primary endpoint occurred in 2.7% (112/4098), 1.4% (54/3910), and 1.2% (8/661) of patients in groups A, B, and C, respectively. In the propensity- -adjusted cohort, low HDL-C level increased the risk of primary endpoint (hazard ratio [HR] 1.755, 95% confidence interval [CI] 1.274-2.417, p = 0.001), whereas high HDL-C level did not reduce this risk (HR 0.562, 95% CI 0.275-1.146, p = 0.113). In the propensity-matched cohort, low HDL-C level increased the risk of primary endpoint (HR 1.716, 95% CI 1.210-2.434, p = 0.002), whereas high HDL-C level reduced this risk (HR 0.449, 95% CI 0.214-0.946, p = 0.035). CONCLUSIONS In AMI patients treated with PCI and statins, low HDL-C level increases the risk of cardiovascular death and recurrent myocardial infarction, whereas high HDL-C level likely reduces the risk of cardiovascular events, especially for ST-elevation myocardial infarction.
Collapse
Affiliation(s)
- Jin Sup Park
- Department of Cardiology, Pusan National University Hospital, Busan, South Korea
- Medical Research Institute, Pusan National University Hospital, Busan, South Korea
| | - Kwang Soo Cha
- Department of Cardiology, Pusan National University Hospital, Busan, South Korea.
- Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
| | - Hye Won Lee
- Department of Cardiology, Pusan National University Hospital, Busan, South Korea
| | - Jun-Hyok Oh
- Department of Cardiology, Pusan National University Hospital, Busan, South Korea
| | - Jung Hyun Choi
- Department of Cardiology, Pusan National University Hospital, Busan, South Korea
| | - Han Cheol Lee
- Department of Cardiology, Pusan National University Hospital, Busan, South Korea
| | - Taek Jong Hong
- Department of Cardiology, Pusan National University Hospital, Busan, South Korea
| | - Myung Ho Jeong
- Department of Cardiology, Chonnam National University Hospital, Gwangju, South Korea
| | - Shung Chull Chae
- Department of Cardiology, Kyungpook National University Hospital, Daegu, South Korea
| | - Young Jo Kim
- Department of Cardiology, Yeungnam University Hospital, Daegu, South Korea
| |
Collapse
|
27
|
Abstract
The transcriptional signature of Kupffer cells & Alveolar macrophages are enriched for lipid metabolism genes. Lipid metabolism may control macrophage phenotype. Dysregulated lipid metabolism in macrophages contributes to disease pathology.
Distinct macrophage populations throughout the body display highly heterogeneous transcriptional and epigenetic programs. Recent research has highlighted that these profiles enable the different macrophage populations to perform distinct functions as required in their tissue of residence, in addition to the prototypical macrophage functions such as in innate immunity. These ‘extra’ tissue-specific functions have been termed accessory functions. One such putative accessory function is lipid metabolism, with macrophages in the lung and liver in particular being associated with this function. As it is now appreciated that cell metabolism not only provides energy but also greatly influences the phenotype and function of the cell, here we review how lipid metabolism affects macrophage phenotype and function and the specific roles played by macrophages in the pathogenesis of lipid-related diseases. In addition, we highlight the current questions limiting our understanding of the role of macrophages in lipid metabolism.
Collapse
Affiliation(s)
- Anneleen Remmerie
- Laboratory of Myeloid Cell Ontogeny and Functional Specialization, VIB-UGent Center for Inflammation Research, Technologiepark 927, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
| | - Charlotte L Scott
- Laboratory of Myeloid Cell Ontogeny and Functional Specialization, VIB-UGent Center for Inflammation Research, Technologiepark 927, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium; Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
| |
Collapse
|
28
|
Chipchura DA, Freyberg Z, Edwards C, Leckband SG, McCarthy MJ. Does the Time of Drug Administration Alter the Metabolic Risk of Aripiprazole? Front Psychiatry 2018; 9:494. [PMID: 30364286 PMCID: PMC6193090 DOI: 10.3389/fpsyt.2018.00494] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Accepted: 09/20/2018] [Indexed: 01/04/2023] Open
Abstract
Antipsychotic drugs cause metabolic abnormalities through a mechanism that involves antagonism of D2 dopamine receptors (D2R). Under healthy conditions, insulin release follows a circadian rhythm and is low at night, and in pancreatic beta-cells, D2Rs negatively regulate insulin release. Since they are sedating, many antipsychotics are dosed at night. However, the resulting reduction in overnight D2R activity may disrupt 24 h rhythms in insulin release, potentially exacerbating metabolic dysfunction. We examined retrospective clinical data from patients treated over approximately 1 year with the antipsychotic drug aripiprazole (ARPZ), a D2R partial agonist. To identify effects of timing on metabolic risk, we found cases treated with ARPZ either in the morning (n = 90) or at bedtime (n = 53), and compared hemoglobin A1c, and six secondary metabolic parameters across the two groups. After controlling for demographic and clinical factors, patients treated with ARPZ at night had a significant decrease in HDL cholesterol, while in patients who took ARPZ in the morning had no change. There was a non-significant trend toward higher serum triglycerides in the patients treated with ARPZ at night vs. morning. There were no group differences in hemoglobin A1c, BMI, total cholesterol, LDL cholesterol, or blood pressure. Patients taking APPZ at night developed a worse lipid profile, with lower HDL cholesterol and a trend toward higher triglycerides. These changes may pose additional metabolic risk factors compared to those who take ARPZ in the morning. Interventions based on drug timing may reduce some of the adverse metabolic consequences of antipsychotic drugs.
Collapse
Affiliation(s)
- Danielle A Chipchura
- VA San Diego Healthcare System, Mental Health Service, San Diego, CA, United States
| | - Zachary Freyberg
- Department of Psychiatry and Cell Biology, University of Pittsburgh, Pittsburgh, PA, United States
| | - Corey Edwards
- VA San Diego Healthcare System, Mental Health Service, San Diego, CA, United States
| | - Susan G Leckband
- VA San Diego Healthcare System, Mental Health Service, San Diego, CA, United States
| | - Michael J McCarthy
- VA San Diego Healthcare System, Mental Health Service, San Diego, CA, United States.,Department of Psychiatry and Center for Circadian Biology, University of California, San Diego, San Diego, CA, United States
| |
Collapse
|
29
|
Singh K, Rohatgi A. Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk. J Thorac Dis 2018; 10:109-112. [PMID: 29600034 PMCID: PMC5863140 DOI: 10.21037/jtd.2017.12.97] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Accepted: 12/12/2017] [Indexed: 01/28/2023]
Affiliation(s)
- Kavisha Singh
- Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA
| | - Anand Rohatgi
- Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA
| |
Collapse
|
30
|
Matsumura K, Tamasawa N, Daimon M. Possible Insulinotropic Action of Apolipoprotein A-I Through the ABCA1/Cdc42/cAMP/PKA Pathway in MIN6 Cells. Front Endocrinol (Lausanne) 2018; 9:645. [PMID: 30425683 PMCID: PMC6218629 DOI: 10.3389/fendo.2018.00645] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Accepted: 10/11/2018] [Indexed: 01/07/2023] Open
Abstract
Aims/Introduction: We studied the mechanisms for the possible insulinotropic action of apolipoprotein (Apo) A-I in mouse insulinoma (MIN6) cells. Materials and Methods: The effects of ApoA-I on cAMP production and glucose-stimulated insulin secretion (GSIS), and the dose dependency (ApoA-I at 5, 10, 25, and 50 μg/ml) were determined using MIN6 cells. The effects of the small-interference ribonucleic acid (siRNA) of ATP-binding cassette transporter A1(ABCA1) and Cell division control protein 42 homolog (Cdc42) on the insulinotropic action of ApoA-I was studied, as well as mRNA and protein levels of ABCA1 and Cdc42. Then, the influence of cAMP inhibitor SQ22536, and the cAMP-dependent protein kinase inhibitor Rp-cAMPS on ApoA-I action were studied. Results: Addition of ApoA-I produced cAMP and increased insulin secretion, dose-dependently in high glucose concentration (25 mmmol/l). and ABCA1 protein and Cdc42 mRNA and protein were also enhanced. Specific ABCA1 and Cdc42 siRNA significantly decreased the effects of ApoA-I on insulin secretion compared with negative controls. Manifestations of ABCA1 and Cdc42 mRNA and protein were less than that of the negative control group. Both cAMP inhibiror (SQ22536) and protein kinases inhibitor (Rp-cAMPS) strongly inhibited the effects of ApoA-I on insulin secretion. Conclusions: We demonstrated that ApoA-I enhances glucose-stimulated insulin release in high glucose at least partially through the ABCA1/Cdc42/cAMP/ Protein kinase A (PKA) pathway.
Collapse
Affiliation(s)
- Koki Matsumura
- Graduate School of Medicine and School of Medicine, Hirosaki University, Hirosaki, Japan
- *Correspondence: Koki Matsumura
| | | | - Makoto Daimon
- Graduate School of Medicine and School of Medicine, Hirosaki University, Hirosaki, Japan
| |
Collapse
|
31
|
Akarsu M, Atalay HA, Canat L, Ozcan M, Arman Y, Aydın S, Cil E, Kutlu O, Tükek T. Endocan is markedly overexpressed in severe erectile dysfunction. Andrologia 2017; 50. [DOI: 10.1111/and.12912] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/09/2017] [Indexed: 12/18/2022] Open
Affiliation(s)
- M. Akarsu
- Department of Internal Medicine; Okmeydanı Training and Research Hospital; Sisli-Istanbul Turkey
| | - H. A. Atalay
- Department of Urology; Okmeydanı Training and Research Hospital; Sisli-Istanbul Turkey
| | - L. Canat
- Department of Urology; Okmeydanı Training and Research Hospital; Sisli-Istanbul Turkey
| | - M. Ozcan
- Department of Internal Medicine; Okmeydanı Training and Research Hospital; Sisli-Istanbul Turkey
| | - Y. Arman
- Department of Internal Medicine; Okmeydanı Training and Research Hospital; Sisli-Istanbul Turkey
| | - S. Aydın
- Department of Internal Medicine; Okmeydanı Training and Research Hospital; Sisli-Istanbul Turkey
| | - E. Cil
- Department of Internal Medicine; Okmeydanı Training and Research Hospital; Sisli-Istanbul Turkey
| | - O. Kutlu
- Department of Internal Medicine; Okmeydanı Training and Research Hospital; Sisli-Istanbul Turkey
| | - T. Tükek
- Department of Internal Medicine; Okmeydanı Training and Research Hospital; Sisli-Istanbul Turkey
| |
Collapse
|
32
|
Abstract
Infection with the human immunodeficiency virus (HIV), and subsequent treatment with antiretroviral therapy (ART), is often associated with perturbations in lipid profiles. Furthermore, persistent inflammation, in spite of suppression of viral replication by ART, likely contributes to modifications in lipid composition and function, exacerbating risk for development of cardiovascular disease (CVD). Increased levels of several pro-inflammatory lipid species, including oxidized low-density lipoprotein (LDL) and high-density lipoprotein (HDL), have been measured in HIV-infected persons and are associated with markers of immune activation. The mechanisms linked to this bidirectional relationship in which inflammation increases lipid levels and promotes their modification, and these modified lipid species perpetuate inflammatory processes, require further investigation. Treatment with statins and other lifestyle modifications, including improvement in dietary intake and exercise, are critical to reducing CVD risk. Well-designed clinical trials that take into account the complex relationships among lipids and inflammation within persons infected with HIV need to be considered.
Collapse
Affiliation(s)
- Nicholas T Funderburg
- School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, Ohio State University, 453 W. 10th Ave., 535A Atwell Hall, Columbus, OH, 43210, USA
| | - Nehal N Mehta
- Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, Bethesda, MD, 20892, USA.
| |
Collapse
|
33
|
Jung KY, Kim KM, Han SK, Yun HM, Oh TJ, Choi SH, Park KS, Jang HC, Lim S. Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia. Circ J 2017; 82:1387-1395. [PMID: 28943594 DOI: 10.1253/circj.cj-17-0411] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Quality and quantity of high-density lipoprotein cholesterol (HDL-C) may be associated with cardiovascular risk. We investigated the effect of rosuvastatin on cholesterol efflux (CE) for HDL function and vascular health.Methods and Results:We enrolled 30 dyslipidemic patients with type 2 diabetes mellitus and 20 healthy subjects as controls. Vascular health was assessed on flow-medicated dilation (FMD), nitroglycerin-induced dilatation of the brachial artery and carotid artery intima-media thickness (cIMT). These parameters were compared between patients and controls, and between baseline and at 12 weeks of treatment with rosuvastatin 20 mg. Age and body mass index were 49.8±11.3 years and 25.8±3.7 kg/m2in the patients, and 28.8±3.2 years and 22.4±2.4 kg/m2in the controls, respectively. The biomarkers related to lipid and glucose metabolism and lipoprotein (a), high-sensitivity C-reactive protein, and cIMT were significantly higher, and CE and FMD were significantly lower in the patients than in the controls. In the patients, rosuvastatin 20 mg decreased low-density lipoprotein cholesterol by 54.1% and increased HDL-C by 4.8%. The CE increased significantly after rosuvastatin treatment (12.26±2.72% vs. 14.05±4.14%). FMD also increased, and lipoprotein (a) and cIMT decreased significantly and were associated with changes of CE. CONCLUSIONS Rosuvastatin-induced changes in HDL function are significantly associated with cardiovascular benefit.
Collapse
Affiliation(s)
- Kyong Yeun Jung
- Department of Internal Medicine, Eulji General Hospital.,Department of Internal Medicine, Seoul National University Bundang Hospital
| | - Kyoung Min Kim
- Department of Internal Medicine, Seoul National University Bundang Hospital.,Department of Internal Medicine, Seoul National University College of Medicine
| | - Sun Kyoung Han
- Department of Internal Medicine, Seoul National University College of Medicine
| | - Han Mi Yun
- Physiologic Diagnostic Laboratory, Vascular Laboratory, Seoul National University Bundang Hospital
| | - Tae Jung Oh
- Department of Internal Medicine, Seoul National University Bundang Hospital.,Department of Internal Medicine, Seoul National University College of Medicine
| | - Sung Hee Choi
- Department of Internal Medicine, Seoul National University Bundang Hospital.,Department of Internal Medicine, Seoul National University College of Medicine
| | - Kyong Soo Park
- Department of Internal Medicine, Seoul National University College of Medicine
| | - Hak Chul Jang
- Department of Internal Medicine, Seoul National University Bundang Hospital.,Department of Internal Medicine, Seoul National University College of Medicine
| | - Soo Lim
- Department of Internal Medicine, Seoul National University Bundang Hospital.,Department of Internal Medicine, Seoul National University College of Medicine
| |
Collapse
|
34
|
Brodeur MR, Rhainds D, Charpentier D, Mihalache-Avram T, Mecteau M, Brand G, Chaput E, Perez A, Niesor EJ, Rhéaume E, Maugeais C, Tardif JC. Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys. J Lipid Res 2017; 58:1282-1291. [PMID: 28515138 PMCID: PMC5496027 DOI: 10.1194/jlr.m068940] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 05/12/2017] [Indexed: 12/21/2022] Open
Abstract
Inhibition of cholesteryl ester transfer protein (CETP) increases HDL cholesterol (HDL-C) levels. However, the circulating CETP level varies and the impact of its inhibition in species with high CETP levels on HDL structure and function remains poorly characterized. This study investigated the effects of dalcetrapib and anacetrapib, the two CETP inhibitors (CETPis) currently being tested in large clinical outcome trials, on HDL particle subclass distribution and cholesterol efflux capacity of serum in rabbits and monkeys. New Zealand White rabbits and vervet monkeys received dalcetrapib and anacetrapib. In rabbits, CETPis increased HDL-C, raised small and large α-migrating HDL, and increased ABCA1-induced cholesterol efflux. In vervet monkeys, although anacetrapib produced similar results, dalcetrapib caused opposite effects because the LDL-C level was increased by 42% and HDL-C decreased by 48% (P < 0.01). The levels of α- and preβ-HDL were reduced by 16% (P < 0.001) and 69% (P < 0.01), resulting in a decrease of the serum cholesterol efflux capacity. CETPis modulate the plasma levels of mature and small HDL in vivo and consequently the cholesterol efflux capacity. The opposite effects of dalcetrapib in different species indicate that its impact on HDL metabolism could vary greatly according to the metabolic environment.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Anne Perez
- F. Hoffmann-La Roche Ltd., Basel, Switzerland
| | | | - Eric Rhéaume
- Montreal Heart Institute, Montreal, Quebec, Canada; Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
| | | | - Jean-Claude Tardif
- Montreal Heart Institute, Montreal, Quebec, Canada; Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
| |
Collapse
|
35
|
van der Krieken SE, Popeijus HE, Konings M, Dullens SP, Mensink RP, Plat J. C/EBP-β Is Differentially Affected by PPARα Agonists Fenofibric Acid and GW7647, But Does Not Change Apolipoprotein A-I Production During ER-Stress and Inflammation. J Cell Biochem 2016; 118:754-763. [DOI: 10.1002/jcb.25731] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 09/09/2016] [Indexed: 12/14/2022]
Affiliation(s)
- Sophie E. van der Krieken
- Department of Human Biology; NUTRIM School of Nutrition and Translational Research in Metabolism; Maastricht University; P.O. Box 616; Maastricht 6200 MD The Netherlands
| | - Herman E. Popeijus
- Department of Human Biology; NUTRIM School of Nutrition and Translational Research in Metabolism; Maastricht University; P.O. Box 616; Maastricht 6200 MD The Netherlands
| | - Maurice Konings
- Department of Human Biology; NUTRIM School of Nutrition and Translational Research in Metabolism; Maastricht University; P.O. Box 616; Maastricht 6200 MD The Netherlands
| | - Stefan P.J. Dullens
- Department of Human Biology; NUTRIM School of Nutrition and Translational Research in Metabolism; Maastricht University; P.O. Box 616; Maastricht 6200 MD The Netherlands
| | - Ronald P. Mensink
- Department of Human Biology; NUTRIM School of Nutrition and Translational Research in Metabolism; Maastricht University; P.O. Box 616; Maastricht 6200 MD The Netherlands
| | - Jogchum Plat
- Department of Human Biology; NUTRIM School of Nutrition and Translational Research in Metabolism; Maastricht University; P.O. Box 616; Maastricht 6200 MD The Netherlands
| |
Collapse
|
36
|
Zhong Y, Sun XX, Zhang P, Qin X, Chen W, Guo Y, Jia Z, Bian H, Li Z. Identification and localization of xylose-binding proteins as potential biomarkers for liver fibrosis/cirrhosis. MOLECULAR BIOSYSTEMS 2016; 12:598-605. [PMID: 26687723 DOI: 10.1039/c5mb00703h] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
In our recent study, we found that the expression levels of total xylose-binding proteins (XBPs) were up-regulated significantly in activated hepatic stellate cells (HSCs); however, the denomination, distribution, and function of the XBPs were uncharted. Herein, 70 XBPs from activated HSCs and 64 XBPs from quiescent HSCs were isolated, identified and annotated. A total of 30 XBPs were up-regulated (all fold change ≥ 1.5, p ≤ 0.05) and 14 XBPs were down-regulated (all fold change ≤ 0.67, p ≤ 0.05) in the activated HSCs. The XBPs were localized at the cytoplasm and cytoplasmic membrane in HSCs and cirrhotic liver tissues by cy/histochemistry. The XBPs (i.e. PDIA6 and CFL2) responsible for the regulation of protein binding were up-regulated and those responsible for the regulation of catalytic activity (i.e. TUBB and MX1) were up-regulated in the activated HSCs. 2 candidates (i.e. PDIA6 and APOA1) were then selected for further verification in the sera of patients with HBV-induced chronic hepatitis/cirrhosis using western blotting and serum microarrays. PDIA6 showed a higher discrimination (Area Under Curves, AUCs = 0.8985, p < 0.0001) relative to APOA1 (AUCs = 0.8738, p < 0.0001) in the sera of patients as biomarker candidate. In conclusion, the precision alteration of the XBPs associated with pathological changes in HSCs during liver fibrosis/cirrhosis may provide pivotal information needed to discover potential glycan-binding protein-related biomarkers for diagnosis of liver fibrosis/cirrhosis and for development of new anti-fibrotic strategies.
Collapse
Affiliation(s)
- Yaogang Zhong
- Laboratory for Functional Glycomics, College of Life Sciences, Northwest University, No. 229 Taibai Beilu, Xi'an 710069, P. R. China.
| | - Xiu-Xuan Sun
- Cell Engineering Research Centre and Department of Cell Biology, Fourth Military Medical University, No. 169 Changle Xilu, Xi'an 710032, P. R. China.
| | - Peixin Zhang
- Laboratory for Functional Glycomics, College of Life Sciences, Northwest University, No. 229 Taibai Beilu, Xi'an 710069, P. R. China.
| | - Xinmin Qin
- Laboratory for Functional Glycomics, College of Life Sciences, Northwest University, No. 229 Taibai Beilu, Xi'an 710069, P. R. China.
| | - Wentian Chen
- Laboratory for Functional Glycomics, College of Life Sciences, Northwest University, No. 229 Taibai Beilu, Xi'an 710069, P. R. China.
| | - Yonghong Guo
- Department of Infectious Diseases, The Second Hospital of Medicine College of Xi'an Jiaotong University, Xi'an 710004, P. R. China
| | - Zhansheng Jia
- Center of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, P. R. China
| | - Huijie Bian
- Cell Engineering Research Centre and Department of Cell Biology, Fourth Military Medical University, No. 169 Changle Xilu, Xi'an 710032, P. R. China.
| | - Zheng Li
- Laboratory for Functional Glycomics, College of Life Sciences, Northwest University, No. 229 Taibai Beilu, Xi'an 710069, P. R. China.
| |
Collapse
|
37
|
Shrestha E, Hussein MA, Savas JN, Ouimet M, Barrett TJ, Leone S, Yates JR, Moore KJ, Fisher EA, Garabedian MJ. Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages. J Biol Chem 2016; 291:11172-84. [PMID: 27026705 DOI: 10.1074/jbc.m116.726729] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Indexed: 11/06/2022] Open
Abstract
Liver X receptors (LXR) are oxysterol-activated nuclear receptors that play a central role in reverse cholesterol transport through up-regulation of ATP-binding cassette transporters (ABCA1 and ABCG1) that mediate cellular cholesterol efflux. Mouse models of atherosclerosis exhibit reduced atherosclerosis and enhanced regression of established plaques upon LXR activation. However, the coregulatory factors that affect LXR-dependent gene activation in macrophages remain to be elucidated. To identify novel regulators of LXR that modulate its activity, we used affinity purification and mass spectrometry to analyze nuclear LXRα complexes and identified poly(ADP-ribose) polymerase-1 (PARP-1) as an LXR-associated factor. In fact, PARP-1 interacted with both LXRα and LXRβ. Both depletion of PARP-1 and inhibition of PARP-1 activity augmented LXR ligand-induced ABCA1 expression in the RAW 264.7 macrophage line and primary bone marrow-derived macrophages but did not affect LXR-dependent expression of other target genes, ABCG1 and SREBP-1c. Chromatin immunoprecipitation experiments confirmed PARP-1 recruitment at the LXR response element in the promoter of the ABCA1 gene. Further, we demonstrated that LXR is poly(ADP-ribosyl)ated by PARP-1, a potential mechanism by which PARP-1 influences LXR function. Importantly, the PARP inhibitor 3-aminobenzamide enhanced macrophage ABCA1-mediated cholesterol efflux to the lipid-poor apolipoprotein AI. These findings shed light on the important role of PARP-1 on LXR-regulated lipid homeostasis. Understanding the interplay between PARP-1 and LXR may provide insights into developing novel therapeutics for treating atherosclerosis.
Collapse
Affiliation(s)
- Elina Shrestha
- From the Department of Microbiology, New York University School of Medicine, New York, New York 10016
| | - Maryem A Hussein
- From the Department of Microbiology, New York University School of Medicine, New York, New York 10016
| | - Jeffery N Savas
- the Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611
| | - Mireille Ouimet
- the Department of Medicine, Division of Cardiology, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, New York 10016, and
| | - Tessa J Barrett
- the Department of Medicine, Division of Cardiology, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, New York 10016, and
| | - Sarah Leone
- From the Department of Microbiology, New York University School of Medicine, New York, New York 10016
| | - John R Yates
- the Department of Chemical Physiology, Scripps Research Institute, La Jolla, California 92037
| | - Kathryn J Moore
- the Department of Medicine, Division of Cardiology, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, New York 10016, and
| | - Edward A Fisher
- the Department of Medicine, Division of Cardiology, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, New York 10016, and
| | - Michael J Garabedian
- From the Department of Microbiology, New York University School of Medicine, New York, New York 10016,
| |
Collapse
|
38
|
Yakushiji E, Ayaori M, Nishida T, Shiotani K, Takiguchi S, Nakaya K, Uto-Kondo H, Ogura M, Sasaki M, Yogo M, Komatsu T, Lu R, Yokoyama S, Ikewaki K. Probucol-Oxidized Products, Spiroquinone and Diphenoquinone, Promote Reverse Cholesterol Transport in Mice. Arterioscler Thromb Vasc Biol 2016; 36:591-7. [PMID: 26848156 DOI: 10.1161/atvbaha.115.306376] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Accepted: 01/21/2015] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Oxidized products of probucol, spiroquinone and diphenoquinone, were shown to increase cell cholesterol release and plasma high-density lipoprotein (HDL) by inhibiting degradation of ATP-binding cassette transporter A1. We investigated whether these compounds enhance reverse cholesterol transport in mice. APPROACH AND RESULTS Spiroquinone and diphenoquinone increased ATP-binding cassette transporter A1 protein (2.8- and 2.6-fold, respectively, P<0.01) and apolipoprotein A-I-mediated cholesterol release (1.4- and 1.4-fold, P<0.01 and P<0.05, respectively) in RAW264.7 cells. However, diphenoquinone, but not spiroquinone, enhanced cholesterol efflux to HDL (+12%, P<0.05), whereas both increased ATP-binding cassette transporter G1 protein, by 1.8- and 1.6-fold, respectively. When given orally to mice, both compounds significantly increased plasma HDL-cholesterol, by 19% and 20%, respectively (P<0.05), accompanied by an increase in hepatic and macrophage ATP-binding cassette transporter A1 but not ATP-binding cassette transporter G1. We next evaluated in vivo reverse cholesterol transport by injecting RAW264.7 cells labeled with (3)H-cholesterol intraperitoneally into mice. Both spiroquinone and diphenoquinone increased fecal excretion of the macrophage-derived (3)H-tracer, by 25% and 28% (P<0.01 and P<0.05), respectively. spiroquinone/diphenoquinone did not affect fecal excretion of HDL-derived (3)H-cholesterol, implying that macrophage-to-plasma was the most important step in spiroquinone/diphenoquinone-mediated promotion of in vivo reverse cholesterol transport. Finally, spiroquinone significantly reduced aortic atherosclerosis in apolipoprotein E null mice when compared with the vehicle. CONCLUSIONS Spiroquinone and diphenoquinone increase functional ATP-binding cassette transporter A1 in both the macrophages and the liver, elevate plasma HDL-cholesterol, and promote overall reverse cholesterol transport in vivo. These compounds are promising as therapeutic reagents against atherosclerosis.
Collapse
Affiliation(s)
- Emi Yakushiji
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Makoto Ayaori
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.).
| | - Takafumi Nishida
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Kazusa Shiotani
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Shunichi Takiguchi
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Kazuhiro Nakaya
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Harumi Uto-Kondo
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Masatsune Ogura
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Makoto Sasaki
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Makiko Yogo
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Tomohiro Komatsu
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Rui Lu
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Shinji Yokoyama
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| | - Katsunori Ikewaki
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (E.Y., M.A., T.N., K.S., S.T., K.N., H.U.-K., M.O., M.S., M.Y., T.K., K.I.); and Nutritional Health Science Research Center, Chubu University, Kasugai, Japan (R.L., S.Y.)
| |
Collapse
|
39
|
Arora S, Patra SK, Saini R. HDL—A molecule with a multi-faceted role in coronary artery disease. Clin Chim Acta 2016; 452:66-81. [DOI: 10.1016/j.cca.2015.10.021] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2015] [Revised: 10/13/2015] [Accepted: 10/22/2015] [Indexed: 01/18/2023]
|
40
|
Gunawardane RN, Fordstrom P, Piper DE, Masterman S, Siu S, Liu D, Brown M, Lu M, Tang J, Zhang R, Cheng J, Gates A, Meininger D, Chan J, Carlson T, Walker N, Schwarz M, Delaney J, Zhou M. Agonistic Human Antibodies Binding to Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism. J Biol Chem 2015; 291:2799-811. [PMID: 26644477 PMCID: PMC4742745 DOI: 10.1074/jbc.m115.672790] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Indexed: 11/28/2022] Open
Abstract
Drug discovery opportunities where loss-of-function alleles of a target gene link to a disease-relevant phenotype often require an agonism approach to up-regulate or re-establish the activity of the target gene. Antibody therapy is increasingly recognized as a favored drug modality due to multiple desirable pharmacological properties. However, agonistic antibodies that enhance the activities of the target enzymes are rarely developed because the discovery of agonistic antibodies remains elusive. Here we report an innovative scheme of discovery and characterization of human antibodies capable of binding to and agonizing a circulating enzyme lecithin cholesterol acyltransferase (LCAT). Utilizing a modified human LCAT protein with enhanced enzymatic activity as an immunogen, we generated fully human monoclonal antibodies using the XenoMouseTM platform. One of the resultant agonistic antibodies, 27C3, binds to and substantially enhances the activity of LCAT from humans and cynomolgus macaques. X-ray crystallographic analysis of the 2.45 Å LCAT-27C3 complex shows that 27C3 binding does not induce notable structural changes in LCAT. A single administration of 27C3 to cynomolgus monkeys led to a rapid increase of plasma LCAT enzymatic activity and a 35% increase of the high density lipoprotein cholesterol that was observed up to 32 days after 27C3 administration. Thus, this novel scheme of immunization in conjunction with high throughput screening may represent an effective strategy for discovering agonistic antibodies against other enzyme targets. 27C3 and other agonistic human anti-human LCAT monoclonal antibodies described herein hold potential for therapeutic development for the treatment of dyslipidemia and cardiovascular disease.
Collapse
Affiliation(s)
| | | | | | - Stephanie Masterman
- Therapeutic Discovery, Amgen Inc., Burnaby, British Columbia V5A 1V7, Canada
| | - Sophia Siu
- From Therapeutic Discovery, Amgen Inc., Seattle, Washington 98119
| | | | - Mike Brown
- From Therapeutic Discovery, Amgen Inc., Seattle, Washington 98119
| | - Mei Lu
- Therapeutic Discovery, and
| | | | | | - Janet Cheng
- From Therapeutic Discovery, Amgen Inc., Seattle, Washington 98119
| | - Andrew Gates
- From Therapeutic Discovery, Amgen Inc., Seattle, Washington 98119
| | - David Meininger
- From Therapeutic Discovery, Amgen Inc., Seattle, Washington 98119
| | | | - Tim Carlson
- PKDM Department, Amgen Inc., South San Francisco, California 94080, and
| | | | | | - John Delaney
- Therapeutic Discovery, Amgen Inc., Burnaby, British Columbia V5A 1V7, Canada
| | | |
Collapse
|
41
|
Ogura M, Hori M, Harada-Shiba M. Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol 2015; 36:181-8. [PMID: 26543100 DOI: 10.1161/atvbaha.115.306665] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Accepted: 10/19/2015] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Patients with familial hypercholesterolemia (FH) are at high risk for premature atherosclerotic cardiovascular disease (ASCVD), especially because of long-term exposure to high low-density lipoprotein cholesterol levels. It has been reported that low-density lipoprotein-lowering therapy delays the onset of ASCVD. However, it still remains difficult to prevent it. Therefore, novel biomarkers and therapeutic targets are necessary to evaluate and prevent atherosclerosis in FH. The aim of this study was to investigate associations of cholesterol efflux capacity with the presence of ASCVD and clinical features in patients with heterozygous FH. APPROACH AND RESULTS We measured cholesterol efflux capacity in 227 patients with heterozygous FH under pharmaceutical treatment. Seventy-six (33.5%) of them were known to have ASCVD. In a logistic-regression analysis adjusted for risk factors, increased efflux capacity was associated with decreased risk of ASCVD even after the addition of high-density lipoprotein cholesterol level as a covariate (odds ratio per 1-SD increase, 0.95; 95% confidence interval, 0.90-0.99; P<0.05). Decreased cholesterol efflux capacity was associated with the presence of corneal arcus after adjusting for age and sex. In addition, inverse relationships between cholesterol efflux capacity and Achilles tendon thickness, as well as carotid intima-media thickness, were observed after adjustment for age, sex, and traditional cardiovascular risk factors. CONCLUSIONS Cholesterol efflux capacity was independently and inversely associated with the presence of ASCVD in heterozygous FH. In view of residual risks after treatment with statins, cholesterol efflux capacity might be a novel biomarker and a therapeutic target for preventing atherosclerosis in patients with FH.
Collapse
Affiliation(s)
- Masatsune Ogura
- From the Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.
| | - Mika Hori
- From the Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - Mariko Harada-Shiba
- From the Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| |
Collapse
|
42
|
Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med 2015; 21:1290-7. [PMID: 26501192 DOI: 10.1038/nm.3980] [Citation(s) in RCA: 186] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Accepted: 09/24/2015] [Indexed: 12/16/2022]
Abstract
Genome-wide association studies (GWASs) have linked genes to various pathological traits. However, the potential contribution of regulatory noncoding RNAs, such as microRNAs (miRNAs), to a genetic predisposition to pathological conditions has remained unclear. We leveraged GWAS meta-analysis data from >188,000 individuals to identify 69 miRNAs in physical proximity to single-nucleotide polymorphisms (SNPs) associated with abnormal levels of circulating lipids. Several of these miRNAs (miR-128-1, miR-148a, miR-130b, and miR-301b) control the expression of key proteins involved in cholesterol-lipoprotein trafficking, such as the low-density lipoprotein (LDL) receptor (LDLR) and the ATP-binding cassette A1 (ABCA1) cholesterol transporter. Consistent with human liver expression data and genetic links to abnormal blood lipid levels, overexpression and antisense targeting of miR-128-1 or miR-148a in high-fat diet-fed C57BL/6J and Apoe-null mice resulted in altered hepatic expression of proteins involved in lipid trafficking and metabolism, and in modulated levels of circulating lipoprotein-cholesterol and triglycerides. Taken together, these findings support the notion that altered expression of miRNAs may contribute to abnormal blood lipid levels, predisposing individuals to human cardiometabolic disorders.
Collapse
|
43
|
Nunomura S, Okayama Y, Matsumoto K, Hashimoto N, Endo-Umeda K, Terui T, Makishima M, Ra C. Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells. Allergol Int 2015; 64 Suppl:S11-7. [PMID: 26344074 DOI: 10.1016/j.alit.2015.03.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 02/26/2015] [Accepted: 03/03/2015] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND The activation of liver X receptor (LXR) α or LXRβ negatively regulates the expression of pro-inflammatory genes in mammalian cells. We recently reported that 25-hydroxycholesterol, a representative LXR-activating oxysterol, suppresses IL-6 production in mouse mast cells (MCs) following its engagement of the high-affinity IgE receptor (FcεRI). This finding suggests that murine MCs express functional LXRs; however, the mechanisms underlying the LXR-dependent repression of the MC-mediated production of pro-inflammatory cytokines, including IL-6, are poorly understood. Therefore, we employed the synthetic LXR ligand GW3965 to examine the functions of LXRα and LXRβ in the production of pro-inflammatory cytokines by murine bone marrow-derived MCs (BMMCs). METHODS We prepared BMMCs from wild-type (WT), LXRα(-/-), and LXRα/β(-/-) mice. Each group of BMMCs was pretreated with GW3965 and then stimulated with IgE+antigen (Ag) or lipopolysaccharide (LPS). Cytokine production was then analyzed using specific ELISA kits. RESULTS The activation of LXRs by GW3965 significantly attenuated the production of IL-1α and IL-1β, but not of IL-6, in the WT and LXRα(-/-) BMMCs stimulated with IgE+Ag. However, GW3965 treatment decreased the production of IL-1α, IL-1β, and IL-6 in WT and LXRα(-/-) BMMCs upon stimulation with LPS, while the GW3965-mediated suppression of cytokine production was nearly absent from the LXRα/β(-/-) BMMCs. CONCLUSIONS These findings demonstrate, for the first time, that the activation of LXRs by GW3965 attenuates the antigen- or LPS-induced production of pro-inflammatory cytokines, such as IL-1α and IL-1β, in murine MCs and that LXRβ plays an important role in the LXR-mediated repression of cytokine production.
Collapse
|
44
|
Huang L, Fan B, Ma A, Shaul PW, Zhu H. Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice. J Lipid Res 2015; 56:986-97. [PMID: 25761370 PMCID: PMC4409288 DOI: 10.1194/jlr.m054742] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Revised: 03/05/2015] [Indexed: 01/20/2023] Open
Abstract
ABCA1 plays a key role in the initial lipidation of apoA-I, which generates circulating HDL cholesterol. Whereas it is known that the transcriptional upregulation of ABCA1 promotes HDL formation and reverse cholesterol transport (RCT), it is not known how the inhibition of ABCA1 protein degradation impacts HDL function. Employing the small molecule triacetyl-3-hydroxyphenyladenosine (IMM-H007), we determined how the attenuation of ABCA1 protein degradation affects HDL cholesterol efflux capacity, RCT, and atherosclerotic lesion formation. Pulse-chase analysis revealed that IMM-H007 inhibits ABCA1 degradation and facilitates its cell-surface localization in macrophages, and additional studies in macrophages showed that IMM-H007 thereby promotes cholesterol efflux. IMM-H007 treatment of Paigen diet-fed mice caused an increase in circulating HDL level, it increased the cholesterol efflux capacity of HDL, and it enhanced in vivo RCT from macrophages to the plasma, liver, and feces. Furthermore, ABCA1 degradation suppression by IMM-H007 reduced atherosclerotic plaque formation in apoE(-/-) mice. Thus, via effects on both ABCA1-expressing cells and circulating HDL function, the inhibition of ABCA1 protein degradation by IMM-H007 promotes HDL cholesterol efflux capacity and RCT and attenuates atherogenesis. IMM-H007 potentially represents a lead compound for the development of agents to augment HDL function.
Collapse
Affiliation(s)
- LinZhang Huang
- State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - BaoYan Fan
- State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Ang Ma
- State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Philip W. Shaul
- Center for Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX
| | - HaiBo Zhu
- State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
45
|
Du Y, Wang L, Si S, Yang Y, Hong B. A novel compound 4010B-30 upregulates apolipoprotein A-I gene expression through activation of PPARγ in HepG2 cells. Atherosclerosis 2015; 239:589-98. [DOI: 10.1016/j.atherosclerosis.2015.02.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Revised: 02/10/2015] [Accepted: 02/15/2015] [Indexed: 01/31/2023]
|
46
|
|
47
|
Munger AM, Chow DC, Playford MP, Parikh NI, Gangcuangco LMA, Nakamoto BK, Kallianpur KJ, Ndhlovu LC, Shikuma CM, Mehta NN. Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens. AIDS Res Hum Retroviruses 2015; 31:221-8. [PMID: 25416403 PMCID: PMC4313425 DOI: 10.1089/aid.2014.0239] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
There is an increase in the cardiovascular disease (CVD) morbidity in individuals infected with HIV that may be due to inflammatory lipid modulation not captured by traditional lipid measures. The objective of this study was to perform advanced lipoprotein phenotyping inclusive of the high-density lipoprotein (HDL) cholesterol efflux capacity and lipoprotein particle concentration and size in a well-phenotyped group of 118 patients infected with HIV. We used simple and multivariable analyses to determine the associations between advanced lipoprotein parameters and known cardiometabolic risk factors. Participants were on stable antiretroviral therapy (ART) and had benign traditional lipid panels [median total cholesterol, low-density lipoprotein (LDL)-C, HDL-C, and triglycerides of 178 mg/dl, 108 mg/dl, 44 mg/dl, and 122.5 mg/dl, respectively]. However, advanced lipoprotein phenotyping demonstrated an elevation of LDL particle number (median of 1,233 nmol/liter) and a decrease in LDL size (median of 20.4 nm), along with a decrease in protective, large HDL particles (median of 3.15 μmol/liter) and reduced HDL cholesterol efflux capacity in comparison to controls of other studies. HDL cholesterol efflux capacity was associated with HDL levels (β=0.395, p<0.001), small LDL particle concentration (β=-0.198, p=0.031), insulin sensitivity by the Matsuda index (β=0.218, p=0.029), and the Framingham Risk Score (β=-0.184, p=0.046). We demonstrate an atherogenic lipoprotein profile by NMR spectroscopy and HDL efflux measurement in a group of HIV-infected patients on stable ART with normal lipid panels.
Collapse
Affiliation(s)
- Alana M. Munger
- Hawaii Center for AIDS, University of Hawaii, Honolulu, Hawaii
| | - Dominic C. Chow
- Hawaii Center for AIDS, University of Hawaii, Honolulu, Hawaii
| | - Martin P. Playford
- National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Nisha I. Parikh
- Hawaii Center for AIDS, University of Hawaii, Honolulu, Hawaii
| | | | - Beau K. Nakamoto
- Hawaii Center for AIDS, University of Hawaii, Honolulu, Hawaii
- Straub Clinic and Hospital, Honolulu, Hawaii
| | | | - Lishomwa C. Ndhlovu
- Hawaii Center for AIDS, University of Hawaii, Honolulu, Hawaii
- Department of Tropical Medicine, John A. Burns School of Medicine, Honolulu, Hawaii
| | | | - Nehal N. Mehta
- National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
| |
Collapse
|
48
|
Jiang H, Li CY, Zhou L, Lu B, Lin Y, Huang X, Wei B, Wang Q, Wang L, Lu J. Acne patients frequently associated with abnormal plasma lipid profile. J Dermatol 2015; 42:296-9. [PMID: 25639454 DOI: 10.1111/1346-8138.12761] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2014] [Accepted: 11/26/2014] [Indexed: 12/19/2022]
Affiliation(s)
- Hao Jiang
- Dermatological Department; Clinical Laboratory; Medical Center and Research Department of The First Affiliated Hospital of Guangxi University of Chinese Medicine; Nanning China
| | - Chang Yi Li
- Dermatological Department; Clinical Laboratory; Medical Center and Research Department of The First Affiliated Hospital of Guangxi University of Chinese Medicine; Nanning China
| | - Lu Zhou
- Dermatological Department; Clinical Laboratory; Medical Center and Research Department of The First Affiliated Hospital of Guangxi University of Chinese Medicine; Nanning China
| | - Bin Lu
- Dermatological Department; Clinical Laboratory; Medical Center and Research Department of The First Affiliated Hospital of Guangxi University of Chinese Medicine; Nanning China
| | - Yinghui Lin
- Dermatological Department; Clinical Laboratory; Medical Center and Research Department of The First Affiliated Hospital of Guangxi University of Chinese Medicine; Nanning China
| | - Xiaoqi Huang
- Dermatological Department; Clinical Laboratory; Medical Center and Research Department of The First Affiliated Hospital of Guangxi University of Chinese Medicine; Nanning China
| | - Bin Wei
- Ruikang Hospital; Nanning China
| | | | - Leping Wang
- Dongzhimen Hospital of Beijing University of Chinese Medicine; Beijing China
| | - Jianqi Lu
- Dermatological Department; Clinical Laboratory; Medical Center and Research Department of The First Affiliated Hospital of Guangxi University of Chinese Medicine; Nanning China
| |
Collapse
|
49
|
Wang H, Zhang W, Wan J, Liu W, Yu B, Jin Q, Guan M. Microchip-based human serum atherogenic lipoprotein profile analysis. Anal Biochem 2014; 467:75-83. [DOI: 10.1016/j.ab.2014.08.031] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2014] [Revised: 08/24/2014] [Accepted: 08/25/2014] [Indexed: 10/24/2022]
|
50
|
Cilpa-Karhu G, Jauhiainen M, Riekkola ML. Atomistic MD simulation reveals the mechanism by which CETP penetrates into HDL enabling lipid transfer from HDL to CETP. J Lipid Res 2014; 56:98-108. [PMID: 25424006 DOI: 10.1194/jlr.m054288] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Inhibition of cholesterol ester transfer protein (CETP), a protein mediating transfer of neutral lipids between lipoproteins, has been proposed as a means to elevate atheroprotective HDL subpopulations and thereby reduce atherosclerosis. However, off-target and adverse effects of the inhibition have raised doubts about the molecular mechanism of CETP-HDL interaction. Recent experimental findings have demonstrated the penetration of CETP into HDL. However, atomic level resolution of CETP penetration into HDL, a prerequisite for a better understanding of CETP functionality and HDL atheroprotection, is missing. We constructed an HDL particle that mimics the actual human HDL mass composition and investigated for the first time, by large-scale atomistic molecular dynamics, the interaction of an upright CETP with a human HDL-mimicking model. The results demonstrated how CETP can penetrate the HDL particle surface, with the formation of an opening in the N barrel domain end of CETP, put in evidence the major anchoring role of a tryptophan-rich region of this domain, and unveiled the presence of a phenylalanine barrier controlling further access of HDL-derived lipids to the tunnel of CETP. The findings reveal novel atomistic details of the CETP-HDL interaction mechanism and can provide new insight into therapeutic strategies.
Collapse
Affiliation(s)
- Geraldine Cilpa-Karhu
- Laboratory of Analytical Chemistry, Department of Chemistry, University of Helsinki, FIN-00014 Helsinki, Finland
| | - Matti Jauhiainen
- National Institute for Health and Welfare, Public Health Genomics Unit, Biomedicum, FIN-00251 Helsinki, Finland
| | - Marja-Liisa Riekkola
- Laboratory of Analytical Chemistry, Department of Chemistry, University of Helsinki, FIN-00014 Helsinki, Finland
| |
Collapse
|